<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">872421</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2022.872421</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>System level modeling and analysis of TNF-<italic>&#x3b1;</italic> mediated sphingolipid signaling pathway in neurological disorders for the prediction of therapeutic targets</article-title>
<alt-title alt-title-type="left-running-head">Banaras et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2022.872421">10.3389/fphys.2022.872421</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Banaras</surname>
<given-names>Sanam</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1638513/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Paracha</surname>
<given-names>Rehan Zafar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/446955/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nisar</surname>
<given-names>Maryum</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1341662/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arif</surname>
<given-names>Ayesha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahmad</surname>
<given-names>Jamil</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/236708/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tariq Saeed</surname>
<given-names>Muhammad</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mustansar</surname>
<given-names>Zartasha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shuja</surname>
<given-names>Malik Nawaz</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1055310/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paracha</surname>
<given-names>Rizwan Nasir</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Interdisciplinary Engineering and Sciences (SINES)</institution>, <institution>National University of Sciences and Technology (NUST)</institution>, <addr-line>Islamabad</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Computer Science and Information Technology (CS&#x26;IT)</institution>, <institution>University of Malakand</institution>, <addr-line>Chakdara</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Kohat University of Science and Technology</institution>, <addr-line>Kohat</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Chemistry</institution>, <institution>University of Sargodha</institution>, <institution>Sub Campus Bhakkar</institution>, <addr-line>Bhakkar</addr-line>, <country>Pakistan</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/28605/overview">Zbigniew R. Struzik</ext-link>, The University of Tokyo, Japan</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/642874/overview">Alice Vladimirovna Alessenko</ext-link>, Emanuel Institute of Biochemical Physics (RAS), Russia</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1592222/overview">Filip Je&#x17e;ek</ext-link>, University of Michigan, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Rehan Zafar Paracha, <email>rehan@sines.nust.edu.pk</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Computational Physiology and Medicine, a section of the journal Frontiers in Physiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>872421</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>07</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Banaras, Paracha, Nisar, Arif, Ahmad, Tariq Saeed, Mustansar, Shuja and Paracha.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Banaras, Paracha, Nisar, Arif, Ahmad, Tariq Saeed, Mustansar, Shuja and Paracha</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Sphingomyelin (SM) belongs to a class of lipids termed sphingolipids. The disruption in the sphingomyelin signaling pathway is associated with various neurodegenerative disorders. TNF-<italic>&#x3b1;</italic>, a potent pro-inflammatory cytokine generated in response to various neurological disorders like Alzheimer&#x2019;s disease (AD), Parkinson&#x2019;s disease (PD), and Multiple Sclerosis (MS), is an eminent regulator of the sphingomyelin metabolic pathway. The immune-triggered regulation of the sphingomyelin metabolic pathway <italic>via</italic> TNF-<italic>&#x3b1;</italic> constitutes the sphingomyelin signaling pathway. In this pathway, sphingomyelin and its downstream sphingolipids activate various signaling cascades like PI3K/AKT and MAPK/ERK pathways, thus, controlling diverse processes coupled with neuronal viability, survival, and death. The holistic analysis of the immune-triggered sphingomyelin signaling pathway is imperative to make necessary predictions about its pivotal components and for the formulation of disease-related therapeutics. The current work offers a comprehensive in silico systems analysis of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and downstream signaling cascades <italic>via</italic> a model-based quantitative approach. We incorporated the intensity values of genes from the microarray data of control individuals from the AD study in the input entities of the pathway model. Computational modeling and simulation of the inflammatory pathway enabled the comprehensive study of the system dynamics. Network and sensitivity analysis of the model unveiled essential interaction parameters and entities during neuroinflammation. Scanning of the key entities and parameters allowed us to determine their ultimate impact on neuronal apoptosis and survival. Moreover, the efficacy and potency of the FDA-approved drugs, namely Etanercept, Nivocasan, and Scyphostatin allowed us to study the model&#x2019;s response towards inhibition of the respective proteins/enzymes. The network analysis revealed the pivotal model entities with high betweenness and closeness centrality values including recruit FADD, TNFR_TRADD, act CASP2, actCASP8, actCASP3 and 9, cytochrome C, and RIP_RAIDD which profoundly impacted the neuronal apoptosis. Whereas some of the entities with high betweenness and closeness centrality values like Gi-coupled receptor, actS1PR, Sphingosine, S1P, actAKT, and actERK produced a high influence on neuronal survival. However, the current study inferred the dual role of ceramide, both on neuronal survival and apoptosis. Moreover, the drug Nivocasan effectively reduces neuronal apoptosis <italic>via</italic> its inhibitory mechanism on the caspases.</p>
</abstract>
<kwd-group>
<kwd>neurological disorders</kwd>
<kwd>neurons</kwd>
<kwd>microglia</kwd>
<kwd>TNF-&#x03B1;</kwd>
<kwd>sphingomyelin</kwd>
<kwd>network analysis</kwd>
<kwd>quantitative analysis</kwd>
<kwd>drug repurposing</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Neurological disorders refer to the diseases of the central and peripheral nervous systems that affect the brain, spinal cord, or nerves connecting them. Some of the major neurological disorders include Alzheimer&#x2019;s disease (AD), Parkinson&#x2019;s disease (PD), Multiple sclerosis (MS), and various traumatic central nervous system (CNS) injuries (<xref ref-type="bibr" rid="B15">Chen et al., 2016</xref>). Patients&#x2019; conditions worsen when neurological illnesses are neurodegenerative, resulting in excessive neuronal death and loss. Alzheimer&#x2019;s disease is an incurable, chronic, multifactorial neurodegenerative disorder that ultimately leads to dementia. (<xref ref-type="bibr" rid="B38">Kumar and Singh, 2015</xref>). It is the sixth leading cause of death in the US with 121,499 deaths during the year 2019 (<xref ref-type="bibr" rid="B6">Alzheimer&#x2019;s Association 2021</xref>). Memory loss, language difficulty, depression, lack of intellectual coordination, and agitation are all common psychological and behavioral symptoms of AD. (<xref ref-type="bibr" rid="B29">Haque et al., 2019</xref>). It occurs due to the abnormal accumulation of amyloid <italic>&#x3b2;</italic>-protein in the multiple regions of the brain. Correspondingly, Parkinson&#x2019;s disease is degenerative neuropathological state characterized by prominent neuronal death in substantia nigra (<xref ref-type="bibr" rid="B62">Siciliano et al., 2018</xref>). Substantia nigra is midbrain region responsible for modulating movement and maintaining balance (<xref ref-type="bibr" rid="B22">Eriksen et al., 2009</xref>). The general symptoms of PD include resting tremor, stiffness of limbs and trunk, bradykinesia, sleeping disorder, speech difficulties, and postural instability (<xref ref-type="bibr" rid="B40">Lee and Yankee, 2021</xref>). Current statistics show the second highest prevalence of PD among the neurodegenerative diseases (<xref ref-type="bibr" rid="B51">Orozco et al., 2020</xref>). Multiple Sclerosis is autoimmune neurodegenerative disorder causing demyelination of CNS. The disease targets young adults and has an increasing prevalence worldwide (<xref ref-type="bibr" rid="B46">McGinley et al., 2021</xref>).</p>
<p>The microglial cells are the resident immune cells in the brain parenchyma, dispersed throughout the CNS in a non-heterogeneous manner and constitute 10% of the total glial population. Glial cells are non-neuronal cells within the central (CNS) and peripheral nervous system (PNS) responsible for neuronal protection, development, immunity, and homeostasis (<xref ref-type="bibr" rid="B41">Li et al., 2020</xref>; <xref ref-type="bibr" rid="B9">Basham, 2021</xref>). In neurodegenerative disorders like AD, PD, and MS, the loss of neurons owing to pathogenic insults causes activation and aggregation of microglia around affected brain regions. (<xref ref-type="bibr" rid="B31">Ho, 2019</xref>). The activated microglia generate a pro-inflammatory response by releasing several pro-inflammatory mediators known as cytokines, including tumor necrosis factor-<italic>&#x3b1;</italic> (TNF-<italic>&#x3b1;</italic>), Interleukin (IL)-1<italic>&#x3b2;</italic>, and IL-16, which aggravate neuronal degeneration (<xref ref-type="bibr" rid="B39">Kwon and Koh, 2020</xref>). These cytokines further amplify the inflammatory response by recruiting other immune cells to the affected site (<xref ref-type="bibr" rid="B13">Carniglia et al., 2017</xref>). Neuronal activities such as calcium homeostasis, membrane potential, sleep, synapses, learning, and memory are all regulated by TNF-<italic>&#x3b1;</italic> in the healthy CNS. Moreover, as discussed earlier, TNF-<italic>&#x3b1;</italic> is a proinflammatory mediator involved in generating an innate immune response associated with various neurological disorders. To wit, under normal circumstances, the levels of TNF-<italic>&#x3b1;</italic> consistently regulate the physiological processes under its influence. TNF-<italic>&#x3b1;</italic>, which is released by astrocytes and microglia during pathological conditions such as AD, PD, and MS is a prominent component of the neuroinflammatory response (<xref ref-type="bibr" rid="B50">Olmos and Llad&#xf3;, 2014</xref>).</p>
<p>Sphingolipids are a class of lipids highly enriched in the central nervous system (CNS), and they are essential for the development and maintenance of its functional integrity. TNF-<italic>&#x3b1;</italic> can supervise neuronal survival and apoptosis by modulating the sphingolipid signal transduction pathway at various levels. The process starts with the potential binding of TNF-<italic>&#x3b1;</italic> binds with two of its receptors, namely, tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2) (<xref ref-type="bibr" rid="B12">Cabal-Hierro and Lazo, 2012</xref>). TNFR1 constitutively and ubiquitously expresses across all human tissues, including the brain, whereas TNFR2 expresses primarily in neurons and immune cells. However, both the receptors differ in their intracellular death domain (DD) regions. TNFR1 possesses the death domain (DD) on its cytoplasmic tail, whereas TNFR2 lacks this motif. The binding of TNF-<italic>&#x3b1;</italic> with TNFR1 triggers the initiation of the TNF-<italic>&#x3b1;</italic> signaling pathway. The downstream modulators of TNFR1 activation like TRADD and FADD directly or indirectly mediate the number of signaling cascades besides producing apoptotic effects (<xref ref-type="bibr" rid="B71">Wajant and Siegmund, 2019</xref>). The modulation of nuclear factor-kappa B (NF-<italic>&#x3ba;</italic> B) and sphingomyelin signal transduction pathways <italic>via</italic> TNF-<italic>&#x3b1;</italic> implicates the role of TNF-<italic>&#x3b1;</italic> in neuronal death and survival (<xref ref-type="bibr" rid="B44">Malagarie-Cazenave et al., 2002</xref>). Besides, the sphingomyelin (SM) signaling pathway establishes a distinct linkage between TNF-<italic>&#x3b1;</italic>, PI3K/AKT, and MAPK/ERK pathways. In neuropathological conditions like AD, PD, and MS, microglia and astrocytes release large amounts of TNF-<italic>&#x3b1;</italic> that alter its usual physiological and regulatory effects (<xref ref-type="bibr" rid="B65">Subhramanyam et al., 2019</xref>). Therefore, it can be assumed that the attainment of neuronal survival and apoptotic equilibrium depends on the TNF-<italic>&#x3b1;</italic> concentration in the brain.</p>
<p>Several disease-specific immunization strategies and vaccines has been in clinical studies to boost immune responses against proteins that cause pathological changes in neuroinflammatory disorders. For instance, immunization of transgenic mouse models with <italic>&#x3b2;</italic>-amyloid has given some productive results in the attenuation of Alzheimer-like pathology (<xref ref-type="bibr" rid="B58">Schenk et al., 1999</xref>). In the case of AD, Aducanumab is approved as the first FDA-approved therapy which halts the adverse effects of Alzheimer&#x2019;s by reducing <italic>&#x3b2;</italic>-amyloid from the brain to treat AD patients (<xref ref-type="bibr" rid="B23">Esang and Gupta, 2021</xref>). Similarly, PD medications simply alleviate symptoms but do not prevent the condition from deteriorating. The holistic system analysis of the model of immune-triggered pathways presents a realistic approach for making critical predictions regarding pathway components and disease-related treatments. However, the system analysis of static biological pathways is ineffective compared to the system-level dynamic analysis of pathways. Qualitative and Quantitative Analysis are the two standard methodologies used for dynamic system analysis of biological pathways.</p>
<p>Previously, <xref ref-type="bibr" rid="B18">Cho et al., (2003)</xref> studied a mathematical model of the TNF-<italic>&#x3b1;</italic>-mediated NF-<italic>&#x3ba;</italic>B pathway (<xref ref-type="bibr" rid="B18">Cho et al., 2003</xref>). Using the Monte Carlo method, sensitivity analysis of model parameters was performed to identify key proteins and parameters. In two quite a similar studies, the mathematical model of TNF-<italic>&#x3b1;</italic> initiated survival and apoptotic cascades were designed using mass-action kinetics. The model dynamics and results were compared with the experimental findings (<xref ref-type="bibr" rid="B55">Rangamani and Lawrence, 2007</xref>; <xref ref-type="bibr" rid="B16">Chignola et al., 2009</xref>). Moreover,<xref ref-type="bibr" rid="B4">Alvarez-Vasquez et al., (2004)</xref> constructed integrative dynamical mathematical models for sphingolipid metabolism in yeast using kinetic information from literature for the first time (<xref ref-type="bibr" rid="B4">Alvarez-Vasquez et al., 2004</xref>). In another study conducted for <italic>Saccharomyces cerevisiae</italic>, a mathematical model of sphingolipid metabolism using flux-balance analysis was designed and validated experimentally. Simulations of the model precisely manifested the effect of various perturbations that were in exact accordance with the post hoc experimental findings (<xref ref-type="bibr" rid="B4">Alvarez-Vasquez et al., 2004</xref>). Furthermore, in another study, the sphingolipid metabolic pathway was analyzed to study the control aspects of the diauxic shift in yeast (<xref ref-type="bibr" rid="B5">Alvarez-Vasquez et al., 2007</xref>). Likewise, various computational modeling techniques have been employed to model pathological signaling in several neurodegenerative disorders. A comparatively recent and advanced study proposed a comprehensive computational model for the sphingolipid metabolism (<xref ref-type="bibr" rid="B73">Wronowska et al., 2015</xref>). The study used several model analysis methods to detect sensitive and experimentally non-identifiable parameters in the sphingolipid pathway. Also, the model was employed to understand the underlying molecular mechanisms of the sphingolipid metabolism in AD. A recent computational study explored the role of network dynamics towards the initiation and progression of AD (<xref ref-type="bibr" rid="B20">Cutsuridis and Moustafa, 2017</xref>).</p>
<p>The current study employs a model-based quantitative approach to conduct in silico systems analysis of TNF-<italic>&#x3b1;</italic> induced sphingomyelin and downstream signaling cascades. To perform quantitative systems analysis, we build a model that depicts TNF-<italic>&#x3b1;</italic> effect on the sphingolipid signaling pathway and incorporates gene intensity values from microarray analysis. The inflammatory process may be studied thoroughly using computational modeling and simulation. The model&#x2019;s network and sensitivity analyses reveal the importance of key interaction parameters and entities in the advanced phases of neuroinflammation. Furthermore, we assess the efficacy and potency of FDA-approved medicines, namely Etanercept, Nivocasan, and Scyphostatin, at later phases of neuronal inflammation by analyzing the model&#x2019;s response to protein/enzyme inhibition. The study identifies new biomarkers, essential and novel system components such as TNFR adaptor proteins or sphingolipids as effective and potential drug targets at inflammatory stages, and investigates drug repurposing.</p>
</sec>
<sec id="s2">
<title>2 Methodology</title>
<p>The current study offers a computational workflow based on the quantitative modeling of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway and its downstream signaling pathways (MAPK and PI3K-AKT). The model was generated in Matlab/Simbiology, based on the data from the literature as well as the KEGG database. The gene expression data from a microarray dataset of AD study were taken as the initial values of the input entities of the model. The transitions of the model were adjusted with the kinetic rates based on the law of mass action. Network analysis and quantitative analyses were then performed, which allowed us to identify and analyze the key entities and interactions of the model. Eventually, the drug-dependent signaling in the model enabled studying the effects of different dosages of drugs and corresponding model responses (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Work-Flow of the study- The analysis starts with the extraction of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway information from literature and KEGG. The step is followed by the construction of the model of extracted pathways in Simbiology. The model is subjected to two forms of analysis: Network Analysis and Quantitative Analysis. The network analysis includes two measures: Betweenness Centrality and Closeness Centrality which help to identify the essential proteins in the model. For the quantitative analysis, the initial concentrations of entities are incorporated in the model from the microarray gene expression data of normal individuals. The measures of quantitative analysis include Simulation of the model&#x2019;s entities, Scanning of entities and parameters, Sensitivity Analysis of entities vs. entities and parameters vs. entities, and the effect of different Drugs&#x2019; Dosages (Etanercept, Nivocasan, and Scyphostatin) over the model. Moreover, the results from Network Analysis and Quantitative Analysis are compared.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g001.tif"/>
</fig>
<sec id="s2-1">
<title>2.1 Pathway extraction</title>
<p>KEGG is a pathway database, which provides the metabolic, genomic, and chemical information for understanding high-level functions of the biological systems (<xref ref-type="bibr" rid="B32">Kanehisa and Goto, 2000</xref>). To model TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and downstream signaling pathways, we extracted the pathway data from the KEGG pathway database as well as literature (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). TNF-<italic>&#x3b1;</italic> initiates the pathway <italic>via</italic> binding with TNF receptors (TNFR1 and TNFR2) (<xref ref-type="fig" rid="F2">Figure 2</xref>). TNFR1 possesses the death domain (DD) on its cytoplasmic tail, whereas TNFR2 lacks this motif <xref ref-type="bibr" rid="B56">Ruiz et al., (2021)</xref>. The binding of TNF-<italic>&#x3b1;</italic> trimer with TNFR1 leads to the receptor trimerization followed by the recruitment of cytosolic adaptor protein called TRADD. The recruitment of TRADD causes the recruitment of three additional adapter proteins, namely, receptor-interacting protein (RIP), TNF receptor-associated factor 2 (TRAF2), and Fas-associated death domain (FADD). The RIP along with RAIDD (another death domain-containing molecule) induces activation of caspase 2, which plays a central role in apoptosis <xref ref-type="bibr" rid="B71">Wajant and Siegmund (2019)</xref>. FADD allows the activation of caspase 8 by interacting with its DED domain (death effector domain) <xref ref-type="bibr" rid="B63">Siegmund et al. (2001)</xref>. TRAF2 is capable of interacting with NIK (NF-<italic>&#x3ba;</italic>B Inducing Kinase) which belongs to the MEKK family. NIK phosphorylates its target IKK (Inhibitor of <italic>&#x3ba;</italic>B Kinase) which ultimately leads to the activation of NF-<italic>&#x3ba;</italic>B. NF-<italic>&#x3ba;</italic>B produces an anti-apoptotic effect by promoting transcription of cellular inhibitor of apoptosis protein 2 (c-IAP2), which blocks the caspase 8 activation and hence apoptosis (<xref ref-type="bibr" rid="B50">Olmos and Llad&#xf3;, 2014</xref>; <xref ref-type="bibr" rid="B14">Chadwick et al., 2008</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>TNF-<italic>&#x3b1;</italic> mediated Sphingomyelin Signaling Pathway- The pathway starts from the binding of TNF-<italic>&#x3b1;</italic> with TNF receptor 1. The binding of TNF-<italic>&#x3b1;</italic> trimer with TNFR1 leads to receptor trimerization. It is followed by the recruitment of three cytosolic adaptor proteins, namely, TRADD, RAIDD, and FAN. TRADD and RAIDD bind with the DD of TNFR1 while FAN binds with its NSD. The recruitment of TRADD causes the recruitment of three additional adapter proteins, namely, RIP, TRAF2, and FADD. The RIP along with RAIDD (another death domain-containing molecule) induces activation of caspase 2, which leads to apoptosis. FADD allows the activation of caspase 8 <italic>via</italic> interacting with its DED domain (death effector domain). TRAF2 is capable of interacting with NIK (NF-<italic>&#x3ba;</italic>B Inducing Kinase) which belongs to the MEKK family. NIK phosphorylates its target IKK (Inhibitor of <italic>&#x3ba;</italic>B Kinase) which ultimately leads to the activation of NF-<italic>&#x3ba;</italic>B. NF-<italic>&#x3ba;</italic>B produces an anti-apoptotic effect by promoting transcription of cellular inhibitor of apoptosis protein 2 (c-IAP2), which blocks the caspase 8 activation and consequently apoptosis. In the sphingolipid metabolic pathway, sphingomyelinases (SMase) catalyze the conversion of sphingomyelin to ceramide. In neurons, ceramide is produced by the hydrolysis of sphingomyelin <italic>via</italic> acidic (A-SMase) or neutral (N-SMase). The activation of both forms of SMases is mediated by the TNF-<italic>&#x3b1;</italic> signaling cascade. The adaptor proteins TRADD and FADD induce the activity of acid SMase, whereas FAN is associated with the activation of neutral SMase. Ceramide, generated in response to acid sphingomyelinase, activates aspartyl protease cathepsin D responsible for the cleavage and activation of pro-apoptotic Bid (family member Bcl-2). The elevated levels of ceramide cause increased permeability of mitochondria which induces the release of cytochrome C from the mitochondria. It causes the activation of caspases 3 and 9, ultimately leading to apoptosis <italic>via</italic> an intrinsic pathway. On the other hand, ceramide produced <italic>via</italic> neutral sphingomyelinase (nSMase) directly activates two target enzymes, namely, CAPK (ceramide activated protein kinase) and CAPP (ceramide activated protein phosphatase) (<xref ref-type="bibr" rid="B30">Haughey et al., 2010</xref>). Both of them are capable of evoking signaling that leads to apoptosis. CAPK phosphorylates raf-1, which enhances its activity towards MEK (MAPK kinase). The MAPK signaling cascade induces activation of ERK cascade, which either results in cell cycle arrest and cell death or contributes to neuronal cell survival depending upon the form of ERK activated. On the other hand, CAPP (comprising of serine-threonine phosphatases PP1 and PP2A) moves the system towards apoptosis by inactivating Akt.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g002.tif"/>
</fig>
<p>The second messenger functions of sphingolipids allow them to modulate a variety of signaling events in the central nervous system (CNS). In the sphingolipid metabolic pathway, sphingomyelinases (SMase) are of great importance as they catalyze the conversion of sphingomyelin to ceramide. Three types of sphingomyelinases have yet been identified that are categorized based on their optimal pH, i.e., alkaline, acidic, and neutral. In neurons, ceramide is produced by the hydrolysis of sphingomyelin <italic>via</italic> acidic (A-SMase) or neutral (N-SMase) as both of these forms have been identified in the neurons. (<xref ref-type="bibr" rid="B30">Haughey et al., 2010</xref>). The activation of both SMases is mediated by the TNF-<italic>&#x3b1;</italic> signaling cascade. The adaptor proteins TRADD and FADD induce the activity of acid SMase (<xref ref-type="bibr" rid="B72">Wiegmann et al., 1999</xref>), whereas FAN is found to be associated with the activation of neutral SMase (<xref ref-type="bibr" rid="B60">S&#xe9;gui et al., 2001</xref>). It implicates the role of TNF-<italic>&#x3b1;</italic> mediated cytotoxic effects in the regulation of sphingolipid signaling cascade and hence on neuronal survival.</p>
<p>Ceramide, generated in response to acid sphingomyelinase, activates aspartyl protease cathepsin D responsible for the cleavage and activation of pro-apoptotic Bid (family member Bcl-2). The elevated levels of ceramide cause increased permeability of mitochondria which induces the release of cytochrome C from the mitochondria. It causes the activation of caspases 3 and 9, ultimately leading to apoptosis <italic>via</italic> an intrinsic pathway. On the other hand, ceramide produced <italic>via</italic> neutral sphingomyelinase (nSMase) directly activates two target enzymes, namely, CAPK (ceramide activated protein kinase) and CAPP (ceramide activated protein phosphatase) (<xref ref-type="bibr" rid="B30">Haughey et al., 2010</xref>). Both of them are capable of evoking signaling that leads to apoptosis. CAPK phosphorylates raf-1, which enhances its activity towards MEK (MAPK kinase). The MAPK signaling cascade induces activation of ERK cascade, which either results in cell cycle arrest and cell death or contributes to neuronal cell survival depending upon the form of ERK activated. On the other hand, CAPP (comprising of serine-threonine phosphatases PP1 and PP2A) moves the system towards apoptosis by inactivating Akt (<xref ref-type="bibr" rid="B30">Haughey et al., 2010</xref>).</p>
</sec>
<sec id="s2-2">
<title>2.2 Quantitative modeling</title>
<sec id="s2-2-1">
<title>2.2.1 Entities concentrations from the microarray analysis</title>
<p>In the current study, we utilized the gene expression values from the microarray data as the initial concentrations for the input entities of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin pathway model for the purpose of its quantitative analysis. The dataset taken was from the study entitled &#x201c;Expression data from post mortem Alzheimer&#x2019;s disease brains&#x201d; (GEO accession: GSE36980). This data set was selected based on the two selection criteria: it was of <italic>Homo sapiens</italic> origin and was free from any therapy or drug. The data comprised 79 samples from different regions of the brain, out of which 32 samples were from AD patients and 47 from normal individuals. The platform of data was Affymetrix Human Gene 1.0 ST Array[HuGene-1_0-st]. The &#x201c;maEndToEnd&#x201d; (<ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/packages/devel/workflows/html/maEndToEnd.html">http://bioconductor.org/packages/devel/workflows/html/maEndToEnd.html</ext-link>) Bioconductor R package was used for step by step analysis of data (<xref ref-type="bibr" rid="B33">Klaus and Reisenauer, 2016</xref>). First, the quality assessment of data was performed by visualizing data using box plot, PCA plot, and Heatmap (Bioconductor R packages (<xref ref-type="bibr" rid="B33">Klaus and Reisenauer, 2016</xref>; <xref ref-type="bibr" rid="B28">Gu et al., 2016</xref>)). Then linear regression model was fit using the limma R package for obtaining the differentially expressed genes (DEGs). Hence, the use of average gene expressions as the initial values formed a basis for analyzing the effects of variations in normal entities&#x2019; concentrations over the whole model.</p>
</sec>
<sec id="s2-2-2">
<title>2.2.2 Quantitative model building</title>
<p>The model of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway is generated in Simbiology (<xref ref-type="fig" rid="F3">Figure 3</xref>). Simbiology is a MATLAB package provided with programmatic tools to simplify modeling, simulation, and analysis of dynamic biological systems. It uses ordinary differential equations and stochastic solvers to simulate and analyse time-course profiles of the model&#x2019;s entities and parameters (<xref ref-type="bibr" rid="B43">Liu et al., 2010</xref>). It provides three building blocks to model dynamic biological systems, i.e., species, compartments, and reactions. Species represent the dynamic states or the concentrations of biological entities like proteins, enzymes, receptors, ligands, or metabolites. Compartments refer to physically isolated environments having a particular set of species, for instance, any particular cell. However, the reactions describe the type of association/interaction among different species. The type of association may represent several biological processes, such as the transformation of molecules, transport of proteins, the binding process of ligands and receptors, or the binding of substrates with enzymes. According to the principle of kinetic law, all interactions are guided by certain kinetics. (All necessary Simbiology model files are publically available at <ext-link ext-link-type="uri" xlink:href="https://github.com/SanamBanaras/Sphingolipid_Signaling_Pathway.git">https://github.com/SanamBanaras/Sphingolipid_Signaling_Pathway.git</ext-link>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model- The whole model is depicted as a network of species (oval) and interactions (circle) connected by lines/edges. Species represent biological entities (receptors, ligands, proteins, enzymes) of the pathway: green color shows receptors, grape color shows caspases, mauve color shows enzymes related to sphingomyelin pathway, light seagreen color shows sphingolipid molecules, bright green color shows cell survival and red color shows cell death. Interactions 1&#x2013;51 represent processes like transformation, transport, binding/unbinding, activation/inhibition: wine color represents inhibitions. Lines connect species with interactions: red lines show inhibition and dotted lines show read arcs representing reversible effect of enzymes specific to the sphingomyelin pathway. Species with red boundaries have multiple trajectories.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g003.tif"/>
</fig>
<p>Based on mass-balance principle, Simbiology automatically translates the network representation of the model into a set of ordinary differential equations (ODEs), thus, mathematically describing the dynamics of biological systems. If we consider two entities &#x201c;A&#x201d; and &#x201c;B&#x201d; acting as the reactants that interact to form a product &#x201c;C,&#x201d; it can be represented by the reaction:<disp-formula id="e1">
<mml:math id="m1">
<mml:mi>m</mml:mi>
<mml:mi>A</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>n</mml:mi>
<mml:mi>B</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">k</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>C</mml:mi>
</mml:math>
<label>(1)</label>
</disp-formula>
<disp-formula id="e2">
<mml:math id="m2">
<mml:mfrac>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x3d;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>k</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:mfenced>
<mml:mspace width="0.17em"/>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:math>
<label>(2)</label>
</disp-formula>
<disp-formula id="e3">
<mml:math id="m3">
<mml:mfrac>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x3d;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>k</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:mfenced>
<mml:mspace width="0.17em"/>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:math>
<label>(3)</label>
</disp-formula>
<disp-formula id="e4">
<mml:math id="m4">
<mml:mfrac>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x3d;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>k</mml:mi>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:mfenced>
<mml:mspace width="0.17em"/>
<mml:mfenced open="[" close="]">
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:math>
<label>(4)</label>
</disp-formula>
</p>
<p>The corresponding system of differential equations for the type of interaction between the entities A and B, represented in reaction 1 and model in <xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref>, is given by <xref ref-type="disp-formula" rid="e2">Eqs 2&#x2013;4</xref>. In the above set of differential equations, &#x201c;k&#x201d; represents the rate constant. The rate of reaction can be defined as the speed of a chemical reaction that is proportional to the change in the concentration of reactant or product per unit time. In terms of product, it is the increase in the concentration of a product per unit time and is represented as d[C]/d[t] for the <xref ref-type="disp-formula" rid="e1">Eq. 1</xref>. In terms of reactant, it is the decrease in the concentration of a reactant per unit time and is represented as d[A]/d[t] or d[B]/d[t] for this equation.</p>
<p>According to the law of mass action, the rate of any chemical reaction is directly proportional to the product of concentrations of the reacting entities (concentrations are represented as &#x201c;[]&#x201d;), and each concentration is raised to a power equal to its respective coefficient in the chemical reaction. The coefficients in the chemical equation (reaction), like &#x201c;m&#x201d; and &#x201c;n&#x201d; (in <xref ref-type="disp-formula" rid="e2">Eqs 2</xref>&#x2013;<xref ref-type="disp-formula" rid="e4">4</xref>), indicate the number of molecules of the reactants &#x201c;A&#x201d; and &#x201c;B,&#x201d; respectively. Therefore, for reaction 1, we obtain a corresponding system of differential equations (given by <xref ref-type="disp-formula" rid="e2">Eqs 2</xref>&#x2013;<xref ref-type="disp-formula" rid="e4">4</xref>) representing the rate of chemical reaction according to the law of mass action. We modeled reaction 1 in Simbiology as shown in the <xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref>. For this model, we set the concentration/amount of the reactant &#x201c;A&#x201d; as 20, &#x201c;B&#x201d; as 10, and the value of mass action rate constant &#x201c;k&#x201d; as 1. The simulation run of the model with given settings, as given in <xref ref-type="sec" rid="s11">Supplementary Figure S2B</xref>, over 5-time units shows the decrease in the concentration of reactants &#x201c;A&#x201d; and &#x201c;B,&#x201d; while an increase in the concentration of product &#x201c;C&#x201d;. The concentration of reactant &#x201c;A&#x201d; decreases from 20 to 10, whereas the concentration of reactant B reduces from 10 to 0. However, the amount of product increases from 0 to 10.</p>
<p>The model of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway was constructed as a network of species representing receptors, ligands, enzymes, adaptor proteins or molecules, and interactions representing processes like transformation, transport, activation, inhibition, binding or unbinding; connected by lines (or edges). Each input entity of the model was set to a specific initial value based on its expression profile obtained in the microarray analysis (discussed in <xref ref-type="sec" rid="s3-1">Section 3.1</xref>). Moreover, all the interactions of model were made to follow mass-action kinetics. Accordingly, the kinetic parameter values for interactions were incorporated in the form of mass action kinetics (kf). These values of mass action kinetics were adjusted between 0 and 0.1 (any suitable value between 0 and 0.1) to attain the homeostatic balanced state of the model. The kinetic values were manipulated due to the lack of kinetic data of the model&#x2019;s interactions (<xref ref-type="bibr" rid="B34">Koch et al., 2010</xref>). The model along with its full description is shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. All interactions are given in the <xref ref-type="sec" rid="s11">Supplementary Material Section 1</xref>. The ordinary differential equations (ODEs) representing rates of model interactions are given in <xref ref-type="sec" rid="s11">Supplementary Material Section 2</xref> and the adjusted kinetic parameter values for all interactions are given in the <xref ref-type="sec" rid="s11">Supplementary Material Section 3</xref>.</p>
</sec>
<sec id="s2-2-3">
<title>2.2.3 Network analysis</title>
<p>A network refers to a set of connected elements, in a formal process, it can be modeled as mathematical units called graphs.</p>
<p>Definition 1. A directed graph G &#x3d; (V, E) consists of a finite set of vertices &#x201c;V&#x201d; and a finite set of directed edges &#x201c;E&#x201d; (<xref ref-type="disp-formula" rid="e5">Eq. 5</xref>). An edge E &#x3d; (U, V) connects two vertices U and V and is directed from U to V.<disp-formula id="e5">
<mml:math id="m5">
<mml:mi>E</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2286;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>V</mml:mi>
<mml:mo>&#xd7;</mml:mo>
<mml:mi>V</mml:mi>
</mml:math>
<label>(5)</label>
</disp-formula>
</p>
<p>Different types of biological entities and interactions of the model possess a high significance in systems biology. Network analysis approaches having non-biological bases can be effectively implemented on large and complex biological networks to search pivotal components. One such measure is the centrality analysis of pathway elements, which allows the ranking and identification of significant entities of the model based on their position. For instance, the functional importance of highly connected vertices in protein networks is evident as their removal or deletion can cause lethality (<xref ref-type="bibr" rid="B69">Valente et al., 2008</xref>). The two centrality measures, i.e., betweenness centrality and closeness centrality were applied to the model, which quantified the significance of certain entities among others. Betweenness centrality determines a node&#x2019;s centrality by measuring shortest paths from all vertices to all other vertices of the graph that pass through that node. On the other hand, closeness centrality applied to strongly connected graphs utilizes information about length of the shortest paths within a network. The closeness centrality can be found by taking the reciprocal of the sum of minimal distances of a vertex to all other vertices.Definition 2. Formally, if we denote by <inline-formula id="inf1">
<mml:math id="m6">
<mml:msup>
<mml:mrow>
<mml:mi>&#x3c3;</mml:mi>
<mml:mspace width="0.17em"/>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:msup>
</mml:math>
</inline-formula> the number of shortest paths from x&#x2019; to x&#x201d; and by <inline-formula id="inf2">
<mml:math id="m7">
<mml:msup>
<mml:mrow>
<mml:mi>&#x3c3;</mml:mi>
<mml:mspace width="0.17em"/>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:msup>
</mml:math>
</inline-formula>(x) the number of these shortest paths that go through node x, then the betweenness centrality C<sub>
<italic>B</italic>
</sub>(x) for given node x is defined as<disp-formula id="e6">
<mml:math id="m8">
<mml:mi>C</mml:mi>
<mml:mi>B</mml:mi>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
</mml:mfenced>
<mml:mo>&#x3d;</mml:mo>
<mml:munder>
<mml:mrow>
<mml:mo>&#x2211;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mfrac linethickness="0pt">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2033;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>&#x2208;</mml:mo>
<mml:mi>V</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>&#x2260;</mml:mo>
<mml:mi>x</mml:mi>
<mml:mo>&#x2260;</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2033;</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:munder>
<mml:mfrac>
<mml:mrow>
<mml:mi>&#x3c3;</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2033;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mi>&#x3c3;</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2033;</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:math>
<label>(6)</label>
</disp-formula>
</p>
<p>
<statement>
<p>Definition 3. The closeness centrality C<sub>
<italic>C</italic>
</sub>(x) of a node x in a graph G &#x3d; (V, E, W) is defined as the inverse of the sum of the shortest path lengths from this node to every other node in the graph.<disp-formula id="e7">
<mml:math id="m9">
<mml:mi>C</mml:mi>
<mml:mi>C</mml:mi>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
</mml:mfenced>
<mml:mo>&#x3d;</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:munder>
<mml:mrow>
<mml:mo>&#x2211;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>&#x2208;</mml:mo>
<mml:mi>V</mml:mi>
</mml:mrow>
</mml:munder>
<mml:mi>s</mml:mi>
<mml:mi>G</mml:mi>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>x</mml:mi>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2032;</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mo>&#x2212;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
</mml:math>
<label>(7)</label>
</disp-formula>
</p>
</statement>
</p>
</sec>
<sec id="s2-2-4">
<title>2.2.4 Simulation of the model</title>
<p>Simbiology can simulate the dynamic behavior of the model <italic>via</italic> converting interactions and rate parameters into a set of ordinary differential equations. Different ODE solvers (ODE 15s, ODE 23t) are utilized to compute solutions for ODEs at different times during the simulation. An exemplar simulation run for the model shown in <xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref> is given in the <xref ref-type="sec" rid="s11">Supplementary Figure S2B</xref>. The simulation results show the gradual decrease in reactants A and B concentrations while an increase in product C concentration with mass action kinetic equal to 1. We performed simulation of the generated model of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway to track precisely the minor details of changes in entities&#x2019; concentrations over time (from 0 to 100) till the attainment of the homeostatic state. The relative time unit (RTU) was considered as the unit of time during simulation. The simulation plots mimicked the gradual process of change in the concentrations (quantities) of the entities with respect to time.</p>
</sec>
<sec id="s2-2-5">
<title>2.2.5 Scanning of the model components</title>
<p>The scanning allows determining the trend or changing behavior of the system entities (in the form of varying concentrations) over an alternating range of a particular component of the model (entity or a parameter). In the current study, we conducted two scanning procedures on the model, i.e., Parameter scanning and Entity scanning. The parameter scanning determined the trend or behavior of a model entity (trend of varying concentration) in response to an increase in parameter (kinetic) value of a particular interaction within a specified range. On the other hand, entity scanning depicted an entity&#x2019;s response (trend of changing concentration) towards alternating concentration of a particular model entity over a specified range. In the current study, parameter scanning was performed to observe and determine the effect of alternating kinetics on neuronal homeostasis. Moreover, the adjusted kinetic values were compared with the known kinetic parameter values for some of the interactions (represented by <xref ref-type="disp-formula" rid="e8">Eqs 8</xref>&#x2013;<xref ref-type="disp-formula" rid="e16">16</xref> of TNF-<italic>&#x3b1;</italic> signaling cascade (<xref ref-type="table" rid="T1">Table 1</xref>) to determine and quantify the difference in their impact on neuronal homeostasis. <xref ref-type="table" rid="T1">Table 1</xref> shows the known kinetic rates for some interactions of TNF-<italic>&#x3b1;</italic> signaling cascade along with their tolerable ranges of variations. Moreover, the comparison between the adjusted and literature kinetic values enabled to determine the likelihood of occurrence of adjusted values for the interactions with known kinetic parameter values within tolerable ranges of variation according to <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Interactions with their Kinetic Parameters (concentration in &#x3bc;M and time in seconds) from Literature along with corresponding range of variation.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">interactions</th>
<th align="left">Kinetics (&#x3bc;<italic>M</italic>
<sup>&#x2212;1</sup>
<italic>s</italic>
<sup>&#x2212;1</sup>)</th>
<th align="left">Range of variation</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">TNFR &#x2b; TNF-<italic>&#x3b1;</italic> &#x2192; TNF-<italic>&#x3b1;</italic>_TNFR</td>
<td align="left">0.185</td>
<td align="left">0.00925&#x2013;2.775</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">TRADD &#x2b; TNFR_TNF-<italic>&#x3b1;</italic> &#x2192; TNFR_TRADD</td>
<td align="left">0.185</td>
<td align="left">0.00925&#x2013;2.775</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">TRAF2&#x2b;TNFR_TRADD &#x2192; TRADD_TRAF2</td>
<td align="left">0.185</td>
<td align="left">0.00925&#x2013;2.775</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">RIP1&#x2b;TNFR_TRADD &#x2192; TRADD_RIP1</td>
<td align="left">0.185</td>
<td align="left">-</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">FADD &#x2b; TRADD &#x2192; TRADD_FADD</td>
<td align="left">0.185</td>
<td align="left">0.00925&#x2013;2.775</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">FADD &#x2b; CASP8 &#x2192; CASP8&#x2a;</td>
<td align="left">0.185</td>
<td align="left">-</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">IKK &#x2b; NF<italic>&#x3ba;</italic>B &#x2192; IKK_NF<italic>&#x3ba;</italic>B</td>
<td align="left">0.185</td>
<td align="left">-</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">RIP1&#x2b; CASP8 &#x2192; RIP1_CASP8</td>
<td align="left">0.0925</td>
<td align="left">0.0462&#x2013;0.1387</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<disp-formula id="e8">
<mml:math id="m10">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>&#x3b1;</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.185</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>&#x3b1;</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
</mml:math>
<label>(8)</label>
</disp-formula>
<disp-formula id="e9">
<mml:math id="m11">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>&#x3b1;</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.1</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
</mml:math>
<label>(9)</label>
</disp-formula>
<disp-formula id="e10">
<mml:math id="m12">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi>&#x3b1;</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.185</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
</mml:math>
<label>(10)</label>
</disp-formula>
<disp-formula id="e11">
<mml:math id="m13">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>F</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.185</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
</mml:math>
<label>(11)</label>
</disp-formula>
<disp-formula id="e12">
<mml:math id="m14">
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>k</mml:mi>
<mml:mi>B</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>p</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>K</mml:mi>
<mml:mi>K</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.185</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>a</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>k</mml:mi>
<mml:mi>B</mml:mi>
</mml:math>
<label>(12)</label>
</disp-formula>
<disp-formula id="e13">
<mml:math id="m15">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>F</mml:mi>
<mml:mn>2</mml:mn>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.185</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>T</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>F</mml:mi>
<mml:mn>2</mml:mn>
</mml:math>
<label>(13)</label>
</disp-formula>
<disp-formula id="e14">
<mml:math id="m16">
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>F</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>N</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.1</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>R</mml:mi>
<mml:mtext>_</mml:mtext>
<mml:mi>F</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>N</mml:mi>
</mml:math>
<label>(14)</label>
</disp-formula>
<disp-formula id="e15">
<mml:math id="m17">
<mml:mi>S</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>P</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>S</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>P</mml:mi>
<mml:mi>R</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.1</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>a</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>S</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>P</mml:mi>
<mml:mi>R</mml:mi>
</mml:math>
<label>(15)</label>
</disp-formula>
<disp-formula id="e16">
<mml:math id="m18">
<mml:mi>A</mml:mi>
<mml:mi>K</mml:mi>
<mml:mi>T</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>P</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>P</mml:mi>
<mml:mn>3</mml:mn>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.1</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>K</mml:mi>
<mml:mi>T</mml:mi>
</mml:math>
<label>(16)</label>
</disp-formula>
</sec>
<sec id="s2-2-6">
<title>2.2.6 Sensitivity analysis</title>
<p>Sensitivity analysis determines the sensitivity or susceptibility of species (entities) or parameters (kinetics) in a model to a specific condition defined by a species or parameter. In Simbiology, the sensitivity analysis is supported by ODE solvers and is categorized into two classes, i.e., local sensitivity analysis and global sensitivity analysis. Local sensitivity is a one at time (OAT) technique that analyzes the effect of a single parameter while keeping all the others fixed. On the other hand, global sensitivity calculation involves the manipulation of collective parameters to explore the design space. Furthermore, the sensitivity analysis can be conducted in two ways, i.e., species (entities) versus parameters (kinetics) or species (entities) versus species (entities). We performed both forms of sensitivity analysis on the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin pathway model. We took all the reaction (interaction) parameters as inputs and entities as outputs to determine the sensitivities of entities in response to reaction (interaction) parameters. Likewise, we determined the influence of the model entities on other entities by selecting all entities as both the input and output.</p>
</sec>
<sec id="s2-2-7">
<title>2.2.7 Intervention of drugs in the model and their response</title>
<p>Different neuropathologies including immune disease, trauma, and inflammation may lead to rapid and irreversible neurological damage. However, various pharmacological treatments have been formulated and applied for the aforementioned neurological disorders and many other diseases. Etanercept, a TNF-<italic>&#x3b1;</italic> antagonist is used as a TNF-<italic>&#x3b1;</italic> blocker to minimize the neurological damage mediated by TNF-dependent processes (<xref ref-type="bibr" rid="B36">Kondziella and Waldemar, 2017</xref>). Nivocasan is an irreversible inhibitor of caspase 1, caspase 8, and caspase 9 (<xref ref-type="bibr" rid="B37">Kudelova et al., 2015</xref>), and is recommended for the apoptosis-mediated liver injury (<xref ref-type="bibr" rid="B1">Adriaenssens, 2017</xref>). Scyphostatin inhibits the neutral SMase (<xref ref-type="bibr" rid="B52">Pitsinos et al., 2003</xref>) and is implicated in lowering the apoptotic effects by decreasing ceramide production.</p>
<p>Pharmacokinetic modeling in Simbiology offers a mathematical approach for predicting the effectiveness and efficacy of drug dosage on the model over time. Using this approach, we assessed the efficacy of three drugs, namely, Etanercept, Nivocasan, and Scyphostatin on TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model. These drugs were assimilated as species in our model, and each drug was analyzed individually. The combined analysis of each drug involving simulation (described in <xref ref-type="sec" rid="s2-2-4">Section 2.2.4</xref>), scanning (described in <xref ref-type="sec" rid="s2-2-5">Section 2.2.5</xref>), and dosing schedule enabled to study a comprehensive model&#x2019;s response towards it. The &#x201c;dosing&#x201d; allows to assimilate the quantity of a specific species (taken as a drug) in model during simulation. In the current study, we adapted the repeat dose strategy to analyze the influence of three mentioned drugs on neuronal apoptosis and survival.</p>
<p>The information of relevant drugs or bioactive molecules having drug-like properties can be obtained using the CHEMBL database (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</ext-link>). For the current model, the targets were selected based on two factors, i.e., availability of FDA-approved drugs and the potency of both drugs and targets to lower neuronal apoptosis. The details of drugs against which the model&#x2019;s response was studied is given in <xref ref-type="table" rid="T2">Table 2</xref>, indicating the name of the drugs along with their targets and mode of mechanism. The model showing drugs with their corresponding site of action is given in <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Drugs for TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway from CHEMBL (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</ext-link>).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Drug Name</th>
<th align="left">Chembl ID</th>
<th align="left">Target</th>
<th align="left">Mechanism</th>
<th align="left">IC50</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Etanercept</td>
<td align="left">Chembl1201572</td>
<td align="left">TNF-<italic>&#x3b1;</italic>
</td>
<td align="left">TNF-<italic>&#x3b1;</italic> inhibition</td>
<td align="left">10<sup>&#x2013;12</sup>
</td>
<td align="left">
<xref ref-type="bibr" rid="B67">Tobinick (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Nivocasan</td>
<td align="left">Chembl2105721</td>
<td align="left">CASP 8, CASP 9</td>
<td align="left">CASP 8,9 inhibition</td>
<td align="left">-</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left">Scyphostatin</td>
<td align="left">Chembl418376</td>
<td align="left">NSMase</td>
<td align="left">Inhibitory activity against NSMase</td>
<td align="left">10<sup>&#x2013;6</sup>
</td>
<td align="left">
<xref ref-type="bibr" rid="B52">Pitsinos et al. (2003)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="s3">
<title>3 Results</title>
<p>We have studied the dynamics of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway in neurons not only under normal circumstances but in a diseased scenario as well. Microglia and astrocytes release a large amount of TNF-<italic>&#x3b1;</italic> to recompense various pathological afflictions like AD and PD (<xref ref-type="bibr" rid="B64">Smith et al., 2012</xref>). The difference in the levels of TNF-<italic>&#x3b1;</italic> causes an imbalance of TNF-<italic>&#x3b1;</italic> regulated signaling cascades having direct or indirect linkage. It eventually alters the equilibrium ratio of neuronal survival and apoptosis. The quantitative modeling of TNF-<italic>&#x3b1;</italic> modulated mechanisms using the Systems Biology approach rendered a distinctive merging of quantitative experimental data with dynamic mathematical modeling, thus providing deeper insights to the model. The quantitative analysis of the model helps to determine the behavior of TNFR-associated adaptor proteins, along with their impact on sphingolipids and enzymes. Moreover, it enables to determine the efficacy and potency of a range of drugs therapeutically active for specific targets in the model by scrutinizing the model response towards different drugs&#x2019; dosages.</p>
<sec id="s3-1">
<title>3.1 Quantitative model building and microarray analysis</title>
<p>The model of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and downstream signaling pathways was built in Simbiology (<xref ref-type="fig" rid="F3">Figure 3</xref>) previously described in <xref ref-type="sec" rid="s2-2-2">Section 2.2.2</xref>. An estimation of initial concentrations for input entities of the model from microarray gene expression data was imperative for envisioning their normal profile in the brain. The names of input model receptors, adaptor proteins and enzymes along with their gene ID&#x2019;s and average gene expression are given in <xref ref-type="table" rid="T3">Table 3</xref>. Moreover, the values of three entities, i.e., SM, CAPK, and mitochondria were assumed due to the lack of availability of their expression data. Therefore, we calculated the values of these entities by taking an average of the gene expression values of remaining model entities having known gene expression values.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Average gene expression values of Model Input Entities obtained from the analysis of Microarray Dataset (GSE36980).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Gene ID</th>
<th align="left">Description</th>
<th align="left">Average gene expression</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">7897877</td>
<td align="left">TNFR</td>
<td align="left">8.243984468</td>
</tr>
<tr>
<td align="left">8177983</td>
<td align="left">TNF-<italic>&#x3b1;</italic>
</td>
<td align="left">6.536676383</td>
</tr>
<tr>
<td align="left">7957560</td>
<td align="left">RAIDD</td>
<td align="left">7.788116383</td>
</tr>
<tr>
<td align="left">7941927</td>
<td align="left">RIP</td>
<td align="left">8.26486</td>
</tr>
<tr>
<td align="left">8136869</td>
<td align="left">CASP 2</td>
<td align="left">8.382271277</td>
</tr>
<tr>
<td align="left">8001938</td>
<td align="left">TRADD</td>
<td align="left">8.054042766</td>
</tr>
<tr>
<td align="left">7942168</td>
<td align="left">FADD</td>
<td align="left">8.231118085</td>
</tr>
<tr>
<td align="left">8047419</td>
<td align="left">CASP 8 (pro CASP 8)</td>
<td align="left">6.960822128</td>
</tr>
<tr>
<td align="left">8159476</td>
<td align="left">TRAF2</td>
<td align="left">7.739208936</td>
</tr>
<tr>
<td align="left">8016194</td>
<td align="left">NIK</td>
<td align="left">7.416519362</td>
</tr>
<tr>
<td align="left">7935707</td>
<td align="left">IKK</td>
<td align="left">8.132140851</td>
</tr>
<tr>
<td align="left">8096635</td>
<td align="left">NFkB</td>
<td align="left">8.291935532</td>
</tr>
<tr>
<td align="left">7943424</td>
<td align="left">cIAP2</td>
<td align="left">8.945781277</td>
</tr>
<tr>
<td align="left">8150928</td>
<td align="left">FAN</td>
<td align="left">9.14069</td>
</tr>
<tr>
<td align="left">7938100</td>
<td align="left">acid_SMase</td>
<td align="left">8.81918234</td>
</tr>
<tr>
<td align="left">8121418</td>
<td align="left">neutral_SMase</td>
<td align="left">8.046917021</td>
</tr>
<tr>
<td align="left">8034762</td>
<td align="left">PKC</td>
<td align="left">11.0</td>
</tr>
<tr>
<td align="left"/>
<td align="left">SM&#x2a;</td>
<td align="left">8.0</td>
</tr>
<tr>
<td align="left"/>
<td align="left">CAPK&#x2a;</td>
<td align="left">8.0</td>
</tr>
<tr>
<td align="left">8114158</td>
<td align="left">CAPP</td>
<td align="left">10.96888511</td>
</tr>
<tr>
<td align="left">7945666</td>
<td align="left">Cathepsin D</td>
<td align="left">11.5453383</td>
</tr>
<tr>
<td align="left">8074261</td>
<td align="left">BID</td>
<td align="left">8.937911064</td>
</tr>
<tr>
<td align="left">8103922</td>
<td align="left">CASP3</td>
<td align="left">7.36558</td>
</tr>
<tr>
<td align="left">7912646</td>
<td align="left">CASP9</td>
<td align="left">8.748945106</td>
</tr>
<tr>
<td align="left">8033151</td>
<td align="left">CDase</td>
<td align="left">6.900429787</td>
</tr>
<tr>
<td align="left">8030078</td>
<td align="left">SPHK</td>
<td align="left">8.642491915</td>
</tr>
<tr>
<td align="left">7903393</td>
<td align="left">S1PR1</td>
<td align="left">8.332580213</td>
</tr>
<tr>
<td align="left">8133860</td>
<td align="left">Gi</td>
<td align="left">9.610689149</td>
</tr>
<tr>
<td align="left">7945436</td>
<td align="left">RasGDP</td>
<td align="left">9.31107383</td>
</tr>
<tr>
<td align="left">7947681</td>
<td align="left">GAP</td>
<td align="left">10.40175149</td>
</tr>
<tr>
<td align="left">8084016</td>
<td align="left">PI3K</td>
<td align="left">9.115858298</td>
</tr>
<tr>
<td align="left">8164328</td>
<td align="left">PIP2</td>
<td align="left">7.307359</td>
</tr>
<tr>
<td align="left">7925531</td>
<td align="left">AKT</td>
<td align="left">11.38724894</td>
</tr>
<tr>
<td align="left">8046408</td>
<td align="left">PDK1</td>
<td align="left">8.90167</td>
</tr>
<tr>
<td align="left">8085164</td>
<td align="left">RAF</td>
<td align="left">9.895470426</td>
</tr>
<tr>
<td align="left">7984319</td>
<td align="left">MEK</td>
<td align="left">10.74989787</td>
</tr>
<tr>
<td align="left">8074791</td>
<td align="left">ERK</td>
<td align="left">12.18609574</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Mitochondria</td>
<td align="left">8.0</td>
</tr>
<tr>
<td align="left">8166402</td>
<td align="left">SMS</td>
<td align="left">9.51</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-2">
<title>3.2 Network analysis</title>
<p>Model of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and associated downstream signaling pathways presented a viable medium for the network analysis (<xref ref-type="fig" rid="F4">Figure 4</xref>). The values for betweenness centrality and closeness centrality of all the entities of model are given in the <xref ref-type="sec" rid="s11">Supplementary Material Section 4 and 5</xref>, respectively. The betweenness centrality results show that the ceramide has the highest value (0.078) among all other entities of the model (<xref ref-type="fig" rid="F4">Figure 4A</xref>). The ranking of the entities betweenness centralities values can be explained by the number and type of interactions with other entities. The ceramide has a total of 13 interactions with other entities, among them, six interactions are incoming while seven are outgoing ones. Likewise, <xref ref-type="bibr" rid="B11">Buccoliero and Futerman (2003)</xref> presented number of evidences indicating the central role of ceramide in the regulation of neuronal survival and apoptosis (<xref ref-type="bibr" rid="B11">Buccoliero and Futerman, 2003</xref>). The rate of dendritic growth is reduced (due to lack of ceramide) in cell line of hippocampal neurons <italic>via</italic> the application of fumonisin B which causes an inhibition of ceramide synthesis (<xref ref-type="bibr" rid="B59">Schwarz and Futerman, 1998</xref>). Moreover, <xref ref-type="bibr" rid="B66">Teitsdottir et al. (2021)</xref> reported high levels of ceramide as a measure of increased AD pathology and their direct impact on neuronal apoptosis during AD pathogenesis <italic>via</italic> cerebrospinal fluid (CSF) lipidomic analysis (<xref ref-type="bibr" rid="B66">Teitsdottir et al., 2021</xref>). The second highest betweenness value is of actSMase (0.051) and has a total of seven interactions (five incoming, two outgoing). The third-largest value is of GiCoupledReceptor (0.031), with a total of 4 interactions (two incoming, two outgoing). The forth is actS1PR (0.03), with a total of three interactions (two incoming, one outgoing). The next value is for Sphingosine (0.029), with a total of six interactions (two incoming, four outgoing). The sixth value is of recruitFADD (0.029), with a total of 4 interactions (two incoming, two outgoing). The seventh value is S1P (0.028), with a total of 3 interactions (two incoming, one outgoing). The eighth value is of TNFR/TRADD (0.022), with a total of five interactions (two incoming, three outgoing). The betweenness values of entities decrease with the number of incoming interactions irrespective of the number of outgoing interactions. Later in the <xref ref-type="sec" rid="s3-3-3-2">Section 3.3.3.2</xref>, the effects of the scanning of these entities on neuronal survival and apoptosis.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<bold>(A)</bold> Betweenness Centrality of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway- Betweenness Centrality of a node represents the number of shortest paths between other pair of nodes that pass through that node. In this figure, the betweenness centralities of the pathway entities are represented by the color and size of the nodes, varying from dark wine to amber yellow and large to small, respectively. Nodes with dark wine color and large size have high betweenness centrality, whereas nodes with light golden color and small size have low betweenness centrality. Color of intermediate nodes vary from punch pink to amber. <bold>(B)</bold> Closeness Centrality of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway- Closeness Centrality of nodes determines their average distance to all other nodes. The closeness centralities of the pathway entities are represented by the color and size of the nodes, varying from dark blue to yellow and large to small respectively. Dark blue nodes with large sizes have high closeness centrality, whereas yellow color nodes having small sizes have low betweenness centrality. Color of intermediate nodes vary from pine green to light green.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g004.tif"/>
</fig>
<p>On the other hand, entities like actCASP2, actCaspase 8, cIAP2, actCAPP, actCaspase 3 and 9, act, and showed the highest closeness centralities with value 1. The highest values suggest their significance because of having a minimum distance from all other entities in the model. Due to this reason, they can serve as the hub entities of the model. Cytochrome C and Caspase 3 and 9 have the second-highest values of 0.75. The high closeness values of caspases signify their involvement in non-apoptotic processes during neuronal development or diseased state (<xref ref-type="bibr" rid="B49">Mukherjee and Williams, 2017</xref>). The closeness centralities of all entities is given in <xref ref-type="fig" rid="F4">Figure 4B</xref>. The effects of scanning of these entities on the neuronal survival and apoptosis later in the <xref ref-type="sec" rid="s3-3-3-3">Section 3.3.3.3</xref>.</p>
</sec>
<sec id="s3-3">
<title>3.3 Quantitative analysis of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model</title>
<p>The comprehensive set of quantitative data in the form of initial concentrations as determined from microarray technique and adjusted reaction (interaction) rates rendered quantitative study and analysis of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin pathway model. The values (or concentrations) for input entities of model were the average gene expressions of normal/healthy conditions. The kinetics parameters of the model&#x2019;s interactions were adjusted between the values 0 to 0.1 with an aim to attain the balanced state of the model in normal/healthy condition. This balanced state of model showed the uniformity in neuronal survival and apoptotic mechanisms, thus, depicting the normal and healthy neuronal conditions. The depiction of a stable neuronal condition was necessary to analyze the effect of any variation (in entity concentration or kinetic parameter) in the diseased state later in our study. The kinetic parameter values of all interactions of the model are provided in the <xref ref-type="sec" rid="s11">Supplementary Material Section 3</xref>.</p>
<sec id="s3-3-1">
<title>3.3.1 Simulation of the model</title>
<p>The simulation run of a model in Simbiology enabled us to track precisely the minor details of even minute changes in entities concentrations over time. <xref ref-type="fig" rid="F5">Figure 5</xref> shows the hypothesized stable (balanced) state of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and related signaling pathways exhibited by fully developed post-mitotic neurons under normal circumstances. It can be noticed that both survival and apoptotic mechanisms (in terms of relative concentration (RC)) function in harmony to keep the system in balance. This is the neuronal physiological state with no influence on the neuronal cell count. The <italic>y</italic>-axis in <xref ref-type="fig" rid="F5">Figure 5</xref> indicates the extent of neuronal survival and apoptotic curves till the attainment of an equilibrium state.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Balanced State of neuronal survival and neuronal apoptosis in mature neurons- Balanced State of neuronal survival and neuronal apoptosis in TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model under normal circumstances. The <italic>y</italic>-axis represents the extent or level (in relative concentration) of neuronal survival and apoptosis. The <italic>x</italic>-axis represents relative time. The two curves, i.e., green and red, are the outcomes of the physiological processes in neurons leading to neuronal survival and death, respectively. The interactive network of signaling pathways keeps neuronal survival and apoptosis in balance (<xref ref-type="bibr" rid="B35">Kole et al., 2013</xref>). A shift in one or more of these signaling pathways can alter the fate of a neuron resulting in neuronal death or continued survival (<xref ref-type="bibr" rid="B48">Morrison et al., 2003</xref>).</p>
</caption>
<graphic xlink:href="fphys-13-872421-g005.tif"/>
</fig>
<p>As evident from <xref ref-type="sec" rid="s11">Supplementary Figure S4A</xref>, TNFR receptor takes approximately 7-8 time units to be occupied by TNF-<italic>&#x3b1;</italic> (having amount 3.4) and FAN (4.74). Also, the activation of caspase 2 (actCASP 2) is at its maximum (0.071) at 12&#x2013;14 time units, and it gradually drops to a minimum of 0.015 in approximately 37-time units.</p>
<p>The formation of TNFR_TRADD reaches the peak value of 0.56 in 3 time units and takes further 6 time units to drop. The recruitment of FADD (recruitFADD) is at the highest with the value 0.0215 in 2 time units and drops to a minimum in 6 time units. Maximum activation of caspase 8 (actCASP 8) takes place in approximately 6 time units (0.038) and then drops to the minimum (0.006) in about 25 time units. The formation of cIAP2 takes place after 3 time units with a rate of 0.1. After that, it reaches its maximum value of 1.4 in nearly 60 time units and then becomes constant. The rate of cIAP2 formation is very high till the attainment of value 1 in the first 20 time units. (<xref ref-type="sec" rid="s11">Supplementary Figure S4B</xref>) The activation of Ceramide activated protein phosphatase (actCAPP) reaches the maximum value of 2.2 in 8&#x2013;10 time units. The constant amount of actCAPP shows its minimum utility in the subsequent interaction possibly because of the small rate. The ceramide production immediately reaches the maximum of 0.52 after 2 units and drops to a minimum of 0.05 right after 10 time units. Similarly, activation of SMase (actSMase) takes place immediately and reaches the maximum 1.48&#xa0;at 2.5 time units for the adjusted rate and drops to a minimum of 0.03 in approximately 10 time units as given in <xref ref-type="sec" rid="s11">Supplementary Figure S4C</xref>.</p>
<p>The release of cytochrome C from mitochondria reaches the maximum (0.235) with 0.1 kinetics in nearly 6 time units. The amount of caspases 3 and 9 starts to decline after 2 time units, and gradually drops to a constant value of 12.7 in 18 time units. The full activation of caspases 3 and 9 takes 9 time units to reach the maximum value of 1.35 with a rate of 0.1 and then drops to the minimum in 65&#x2013;70 time units. (<xref ref-type="sec" rid="s11">Supplementary Figure S4D</xref>). Formation of sphingosine reaches the maximum value of 0.34 in 3 time units and drops to a minimum in 10&#x2013;15 time units. The production of sphingosine-1 phosphate (S1P) attains the peak value of 0.32&#xa0;at 4.5 time units with a rate of 0.1 and takes 15&#x2013;20 time units to drop. The activation of S1PR reaches the peak value of 0.245 in approximately 6.5 time units with a reaction rate of 0.1 and then drops to minimum in 15&#x2013;20 time units. The triggering of the Gi Coupled receptor takes place after 1 time unit and reaches a maximum value of 0.12 in nearly seven time units with the reaction rate of 0.1. Moreover, it takes 18&#x2013;20 time units to reach the minimum (<xref ref-type="sec" rid="s11">Supplementary Figure S4E</xref>) As indicated in <xref ref-type="sec" rid="s11">Supplementary Figure S4F</xref>, the activation of AKT (actAKT) takes place after 3 time units and reaches to the maximum value of 0.33 with the reaction rate of 0.1. However, the activation of ERK (actERK) takes place after 1 time unit and reaches the maximum value of 1.2 in 11&#x2013;12 time units.</p>
</sec>
<sec id="s3-3-2">
<title>3.3.2 Parameter scanning</title>
<p>The interaction 1 of the model is given by <xref ref-type="disp-formula" rid="e8">Eq. 8</xref> which indicates the binding of TNF-<italic>&#x3b1;</italic> with TNFR receptor. Parameter scanning graph for interaction 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>) given in <xref ref-type="fig" rid="F6">Figure 6A</xref> shows a balance between cell survival (green) and cell death (red) at the point of their overlap; where the rate is approximately close to 0.1. It can be traced out that the kinetic parameter value of 0.185 (as give in <xref ref-type="table" rid="T1">Table 1</xref>) shows only a slight (about 0.04) relative increase in cell apoptosis. Besides, the adjusted rate value 0.1 for the current interaction is within the bounds of the range provided in <xref ref-type="table" rid="T1">Table 1</xref>. <xref ref-type="fig" rid="F6">Figure 6A</xref> shows the effect of increasing kinetic parameter on TNFR_TNF-<italic>&#x3b1;</italic> formation. The interaction 2 in the model represented by <xref ref-type="disp-formula" rid="e9">Eq. 9</xref> represents the recruitment of RAIDD after TNFR activation. We adjusted the kinetic parameter value for this interaction as 0.1. <xref ref-type="fig" rid="F6">Figure 6B</xref> shows the intersecting point of two curves representing neuronal survival and apoptosis at a kinetic parameter value of 0.11, which implies the balanced state of the system.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Paramater Scanning of TNF-<italic>&#x3b1;</italic> mediated Sphingolipid Signaling Pathway model interactions with known kinetic parameters from the literature to determine their tolerable range of variations and to study their effect on neuronal survival and death- <bold>(A)</bold> Paramater scanning for interaction 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>) representing TNFR_TNF<italic>&#x3b1;</italic> formation. <bold>(B)</bold> Paramater scanning for interaction 2 (<xref ref-type="disp-formula" rid="e9">Eq. 9</xref>) representing recruitment of RAIDD. <bold>(C)</bold> Paramater scanning for interaction 8 (<xref ref-type="disp-formula" rid="e10">Eq. 10</xref>) representing formation of TNF_TRADD. <bold>(D)</bold> Paramater scanning for interaction 7 (<xref ref-type="disp-formula" rid="e11">Eq. 11</xref>) representing recruitment of FADD. <bold>(E)</bold> Paramater scanning for interaction 9 (<xref ref-type="disp-formula" rid="e12">Eq. 12</xref>) representing NF<italic>&#x3ba;</italic>B activation. <bold>(F)</bold> Paramater scanning for interaction 12 (<xref ref-type="disp-formula" rid="e13">Eq. 13</xref>) representing TRADD_TRAF2 comlex formation. <bold>(G)</bold> Paramater scanning for interaction 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>) representing TNFR_FAN complex formation.<bold>(H)</bold> Paramater scanning for interaction 31 (<xref ref-type="disp-formula" rid="e15">Eq. 15</xref>) representing activation of S1PR. <bold>(I)</bold> Paramater scanning for interaction 38 (<xref ref-type="disp-formula" rid="e16">Eq. 16</xref>) representing recruitment of AKT.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g006.tif"/>
</fig>
<p>The interaction 8 in model representing the formation of the TNFR_TRADD complex is depicted in <xref ref-type="disp-formula" rid="e10">Eq. 10</xref>. In the current model, we adjusted the kinetic parameter value for this interaction as 0.1. The corresponding parameter scanning results are given in <xref ref-type="fig" rid="F6">Figure 6C</xref>. The junction point of neuronal survival and apoptotic plots at the value 0.1 shows the balanced state of the model. This adjusted parameter value has difference of 0.08 units from the value 0.185 as given in <xref ref-type="table" rid="T1">Table 1</xref>, and it lies within the range of variation provided by <xref ref-type="bibr" rid="B18">Cho et al., (2003)</xref>, causing a very slight relative difference of 0.05 units among neuronal apoptosis and survival. The interaction 7 in the model represents the recruitment of FADD which follows the TNFR_TRADD complex formation and is represented by <xref ref-type="disp-formula" rid="e11">Eq. 11</xref>. We adjusted the kinetic parameter value for this interaction as 0.01. Parameter scanning results for this interaction are given by <xref ref-type="fig" rid="F6">Figure 6D</xref> which shows the coinciding point of the neuronal survival and apoptotic curves almost at the adjusted value 0.01. This adjusted value lies within the tolerable range of parameter variation given in <xref ref-type="table" rid="T1">Table 1</xref>, the curves in <xref ref-type="fig" rid="F6">Figure 6D</xref> shows the relative difference of approximately 0.2 units between neuronal apoptosis and survival at a kinetic parameter value of 0.185 from literature.</p>
<p>As discussed earlier, the activation signal for NF<italic>&#x3ba;</italic>B leads to the phosphorylation of IKK, which sequentially triggers the activation of NF<italic>&#x3ba;</italic>B. The interaction 9 in the model represents the NF<italic>&#x3ba;</italic>B activation <italic>via</italic> phIKK and is given by <xref ref-type="disp-formula" rid="e12">Eq. 12</xref>. The adjusted rate value for this interaction is 0.1. The parameter scanning results for this interaction, as given in <xref ref-type="fig" rid="F6">Figure 6E</xref>, show exceptional behaviour as both survival and apoptotic curves move in parallel without coinciding at or near to the adjusted value of 0.1 or the literature value of 0.185 as provided in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<p>The TRADD_TRAF2 complex formation (interaction 12 in the model), as represented by <xref ref-type="disp-formula" rid="e13">Eq. 13</xref>, takes place right after the recruitment of adaptor protein TRADD. The adjusted parameter value used for this interaction in the current model is 0.1, whereas the kinetic parameter value obtained from literature is 0.185 (<xref ref-type="table" rid="T1">Table 1</xref>). The corresponding parameter scanning results are given in <xref ref-type="fig" rid="F6">Figure 6F</xref>. Both the survival and death curves coincide at the adjusted value, which is within the bounds of the range provided by <xref ref-type="table" rid="T1">Table 1</xref>. Additionally, we can observe a very slight relative difference between survival and apoptotic curves at the kinetic value of 0.185 <xref ref-type="bibr" rid="B18">Cho et al. (2003)</xref>. <xref ref-type="disp-formula" rid="e14">Eq. 14</xref> represents the association of FAN with TNFR (which is the interaction 15 in the model). The value of kinetic parameter for the current interaction is adjusted as 0.1. Parameter scanning results in <xref ref-type="fig" rid="F6">Figure 6G</xref> show that the intersecting point of the survival and death curve is nearly around the adjusted value of 0.1. Moreover, the parameter range from 0.02 to 0.2 has no obvious impact on the relative difference between the survival and apoptotic curves.</p>
<p>The binding of S1P with S1PR is represented by <xref ref-type="disp-formula" rid="e15">Eq. 15</xref> (the interaction 31 in the model). The value of kinetic parameter for this ligand-receptor binding was taken as 0.1. The parameter scanning results in <xref ref-type="fig" rid="F6">Figure 6H</xref> indicate that the parameter range 0.02&#x2013;0.2 does not even slightly affect the cell homeostatic state, and the system remains in balance. The recruitment of AKT <italic>via</italic> PIP3 (the interaction 38 in the model) is represented by <xref ref-type="disp-formula" rid="e16">Eq. 16</xref> with the adjusted kinetic parameter value of 0.1 in model. It is evident from the parameter scanning results given in <xref ref-type="fig" rid="F6">Figure 6I</xref> that the parameter range 0.02&#x2013;0.2 has zero influence on neuronal survival and apoptosis. It can be inferred from parameter scanning results for interactions 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>), 2 (<xref ref-type="disp-formula" rid="e9">Eq. 9</xref>), 7 (<xref ref-type="disp-formula" rid="e11">Eq.11</xref>), 8 (<xref ref-type="disp-formula" rid="e10">Eq. 10</xref>), 12 (<xref ref-type="disp-formula" rid="e13">Eq. 13</xref>), 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>), 31 (<xref ref-type="disp-formula" rid="e15">Eq. 15</xref>), and 38 (<xref ref-type="disp-formula" rid="e16">Eq. 16</xref>) that the intersection points of all curves almost coincides with the adjusted parameter kinetics depicting the homeostatic state of the model. Furthermore, except for interaction 9 (<xref ref-type="disp-formula" rid="e12">Eq. 12</xref>), scanning graphs of kinetic parameters over the range 0&#x2013;0.2 for interactions 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>), 7 (<xref ref-type="disp-formula" rid="e11">Eq. 11</xref>), 8 (<xref ref-type="disp-formula" rid="e10">Eq. 10</xref>), and 12 (<xref ref-type="disp-formula" rid="e13">Eq. 13</xref>) show that certain values of kinetic parameters above and below the formulated kinetics are bearable, and do not produce profound effects on neuronal survival and neuronal apoptosis. Their comparison with literature kinetic parameter values (<xref ref-type="bibr" rid="B18">Cho et al., 2003</xref>) shows that they are in accordance and within the bounds of tolerable ranges presented in literature and causes no drastic shift on the homeostatic state of model.</p>
</sec>
<sec id="s3-3-3">
<title>3.3.3 Scanning of entities</title>
<p>TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling model possess various traverses or crosstalks indicating their pivotal role in cell signaling. The presence of multiple trajectories as indicated in <xref ref-type="fig" rid="F3">Figure 3</xref> signifies the importance of TNFR_TNF, TNFR_TRADD, recruited FADD, ceramide, Gi-coupled receptor, actAKT and actERK in the whole model. The quantitative scanning of the various proteins/enzymes serving as the crosstalks and having high centrality measures provides more insights in understanding their behavior towards different perturbations.</p>
<sec id="s3-3-3-1">
<title>3.3.3.1 Scanning of the input entities</title>
<p>It is evident from the scanning results in <xref ref-type="sec" rid="s11">Supplementary Figure S5A</xref> that cell survival remains unaffected with an increase in TNF-<italic>&#x3b1;</italic> concentration, whereas we observe a gradual increase in neuronal death. The adjusted kinetics incorporated in the model shows the exact balance between cell death and cell survival at a concentration of 6.5. The system moves towards apoptosis with a maximum relative difference of 0.2 units in response to a continuous increase in TNF-<italic>&#x3b1;</italic> concentration, as in the case of the diseased scenario. The elevated TNF-<italic>&#x3b1;</italic> levels are reportedly associated with the secondary neuronal damage in traumatic brain injury (TBI) (<xref ref-type="bibr" rid="B8">Baratz et al., 2015</xref>). <xref ref-type="bibr" rid="B8">Baratz et al., (2015)</xref> studied the effect of TNF-<italic>&#x3b1;</italic> synthesis inhibitor 3,6&#x2032;-dithiothalidomide on mice subjected to mild TBI. 3,6&#x2032;-dithiothalidomide ameliorated the neuronal loss, cognitive impairments and elevations in astrocyte number due in response to mild TBI <italic>via</italic> preventing mTBI-induced TNF-<italic>&#x3b1;</italic> elevation <xref ref-type="bibr" rid="B8">Baratz et al., (2015)</xref>.</p>
<p>TRADD shows the exact balance between cell survival and cell death at an adjusted kinetic parameter of 0.1 with an initial concentration of 8 as given by scanning results in <xref ref-type="sec" rid="s11">Supplementary Figure S5B</xref>. The increased stimulation of TRADD in response to TNFR activation slightly moves the system towards apoptosis, whereas the survival mechanisms remain unaffected. The experimental studies show an upregulation of TRADD associated with the cell death machinery in AD patients (<xref ref-type="bibr" rid="B78">Zhao et al., 2003</xref>). The scanning result for the FAN is given by Figure <xref ref-type="sec" rid="s11">Supplementary Figure S5C</xref>. Intersecting point of the graph shows balance in survival and apoptotic mechanisms of the neuron at the normal levels of FAN incorporated in the model. Also, it can be observed that increased concentrations of FAN slightly shifts the equilibrium state of the model by decreasing neuronal apoptosis.</p>
</sec>
<sec id="s3-3-3-2">
<title>3.3.3.2 Scanning of entities with high betweenness centrality</title>
<p>The scanning results of ceramide over the range of values from 0 to 50 are given in <xref ref-type="sec" rid="s11">Supplementary Figure S5C</xref>. The elevation in ceramide levels increases both neuronal survival and apoptosis up to the specified value with the 3-fold relative difference. <xref ref-type="bibr" rid="B68">Toman et al. (2000)</xref> examined the dual role of ceramide in promoting neuronal cell death and apoptosis (<xref ref-type="bibr" rid="B68">Toman et al., 2000</xref>). However, the curve for neuronal survival is slightly higher when compared to the apoptotic curve. It can be justified by the fact that increased levels of ceramide result in an increased activity of CAPK and CDase enzymes, which compels the system towards survival mechanisms. The scanning results of Gi-coupled Receptor over range 0&#x2013;50 are given in Figure <xref ref-type="sec" rid="s11">Supplementary Figure S6B</xref>. Neuronal apoptosis is not affected by increased activation of Gi-Coupled Receptors. On the other hand, the neuronal survival rate increases with a maximum relative difference of about 12 folds among survival and death curves.</p>
<p>The scanning results for recruited FADD are given by <xref ref-type="sec" rid="s11">Supplementary Figure S6C</xref>. An increase in recruitFADD concentration leads to increased neuronal apoptosis up to the specified value of 25 with the relative difference of about 6-folds between survival and apoptotic curves. However, the neuronal survival remains unaffected by the recruitFADD concentration. <xref ref-type="sec" rid="s11">Supplementary Figure S6D</xref> shows the scanning results of TNFR_TRADD. It can be observed that the neuronal survival remains unaffected by an increase in TNFR_TRADD concentration from 0 to 50. However, the neuronal apoptosis increases to the maximum with the relative difference of about 3-folds among survival and death curves. Scanning results for actSMase, actS1PR, Sphingosine, and S1P are given in <xref ref-type="sec" rid="s11">Supplementary Figure S6E&#x2013;H</xref> respectively. The increased levels of actSMase cause a very slight increase in neuronal survival and apoptotic mechanisms with a negligible relative difference of about 0.02 folds. On the other hand, increased levels of actS1PR, sphingosine, and S1P result increase survival mechanism, without affecting neuronal apoptosis, with the relative difference of about 5-6 folds.</p>
</sec>
<sec id="s3-3-3-3">
<title>3.3.3.3 Scanning of entities with high closeness centrality</title>
<p>The scanning of actAKT over range 0&#x2013;50 was performed (<xref ref-type="sec" rid="s11">Supplementary Figure S7A</xref> shows). Neuronal apoptosis remains unaffected from increased levels of actAKT. However, an increase in neuronal survival can be observed with a large relative difference of about 50-folds at actAKT value 50. <xref ref-type="bibr" rid="B21">Endo et al. (2006)</xref> reported an upregulation in Akt signaling during ishemia and other neurodegenerative disorders to mediate neuronal survival (<xref ref-type="bibr" rid="B21">Endo et al., 2006</xref>). The scanning results of actERK as indicated in <xref ref-type="sec" rid="s11">Supplementary Figure S7B</xref> shows no influence of actERK concentration on neuronal apoptosis. However, the impact of actERK on neuronal survival is nearly similar to that caused by actAKT. The increase in actERK value up to 50 leads to increased neuronal survival with the relative difference of about 50-folds.</p>
<p>The scanning results of actCASP2, actCASP8, cIAP2, and actCAPP are given in Figure <xref ref-type="sec" rid="s11">Supplementary Figure S7C&#x2013;F</xref> respectively. The increased levels of actCASP2 and actCASP8 result in increased apoptosis with a large relative difference; without influencing survival rate. The increased levels of cIAP2 cause a slight lowering of neuronal apoptosis with the negligible relative difference of about 0.02 folds. The increased concentration of actCAPP only lowers the survival curve due to its inhibitory effect with a very slight relative difference of about 0.4 folds. The scanning results for actCASP 3and9, Cytochrome C, RIP_RAIDD and actNF<italic>&#x3ba;</italic>B are given in <xref ref-type="sec" rid="s11">Supplementary Figure S7G&#x2013;J</xref> respectively. Increased levels of actCASP 3and9 profoundly affect neuronal apoptosis with a relative difference of about 60-folds. The increased levels of cytochrome C and RIP_RAIDD raise neuronal apoptosis with the relative difference of 15 and 10 folds, respectively. The increased activation of NFkB lowers neuronal apoptosis with a negligible relative difference.</p>
<p>
<xref ref-type="sec" rid="s11">Supplementary Figure S6B</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S7A</xref>, and <xref ref-type="sec" rid="s11">Supplementary Figure S7B</xref> show increasing trends in cell growth with increased activation of Gi-Coupled Receptor, AKT, and ERK respectively. On the other hand, the high levels of recruited FADD (<xref ref-type="sec" rid="s11">Supplementary Figure S6C</xref>) and TNFR_TRADD (<xref ref-type="sec" rid="s11">Supplementary Figure S6D</xref>) having betweenness centrality of 0.02 enhance neuronal apoptosis as evident from the literature. However, despite its suggested role in apoptosis, the increasing levels of ceramide intensify both cell growth and cell death (<xref ref-type="sec" rid="s11">Supplementary Figure S6A</xref>). This contradiction can be explained by the increased activity of CAPK and ceramidase due to elevated ceramide levels, which are capable of potentiating neuronal survival mechanisms. The ERK signaling pathway has a dual role in cell death and survival.</p>
</sec>
</sec>
<sec id="s3-3-4">
<title>3.3.4 Sensitivity analysis</title>
<p>For the acquisition of empirical importance of model parameters and entities upon each other, the whole TNF-<italic>&#x3b1;</italic> mediated sphingomyelin model was subjected to the sensitivity analysis as discussed earlier in the methodology (<xref ref-type="sec" rid="s2">Section 2</xref>).</p>
<sec id="s3-3-4-1">
<title>3.3.4.1 Entities vs. parameters</title>
<p>To study the effect of interaction parameters over entities concentrations, all the interaction parameters (kinetics) were taken as inputs, whereas all model entities were selected as outputs. The results of sensitivity analysis (<xref ref-type="fig" rid="F7">Figure 7A</xref>) unveiled the importance of interaction 1 (<xref ref-type="disp-formula" rid="e8">Eq. (8)</xref> showing TNFR_TNF-<italic>&#x3b1;</italic> binding), interaction 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref> showing TNFR_FAN formation) and interaction 27 (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref> showing Cathepsin D activation); as most of the model entities like SMase, PKC, BID, CASP 3 and 9 were found highly sensitive towards them having sensitivity values greater than 600. Moreover, high influence of interaction 27 (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref> showing Cathepsin D activation), interaction 49 (<xref ref-type="disp-formula" rid="e18">Eq. 18</xref> showing RIP recruitment and interaction 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref> showing ERK-mediated cell death) was observed on neuronal death. The sensitivity values of model entities against interactions parameters are given in the <xref ref-type="sec" rid="s11">Supplementary Material Section 6</xref>. TNF-<italic>&#x3b1;</italic>, FAN, and SMase enzyme showed high sensitivity against interaction 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>). FAN, SMase, TNF-<italic>&#x3b1;</italic>, PKC, and SMase_translocated were highly sensitive to interaction 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>). Protease Cathepsin D, BID, CASP 3and9 were highly responsive to interaction 27 (<xref ref-type="disp-formula" rid="e17">Eq. (17)</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>
<bold>(A)</bold> Sensitivity Analysis of Entities vs. Parameters- The sensitivity analysis graph shows the sensitivities of the entities&#x2019; concentrations over the scale of 0&#x2013;1800 in response to the interaction parameters of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model. <bold>(B)</bold> Sensitivity Analysis of Entities vs. Entities- The sensitivity analysis graph shows the sensitivities of the entities&#x2019; concentrations over the scale of 0&#x2013;100 towards other entities of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g007.tif"/>
</fig>
</sec>
<sec id="s3-3-4-2">
<title>3.3.4.2 Parameter scanning of the interactions having huge impact on neuronal apoptosis and survival</title>
<p>Ceramide is responsible for the activation of protease cathepsin D, which is given by the interaction 27 in the model and <xref ref-type="disp-formula" rid="e17">Eq. 17</xref>. The neuronal apoptosis was found highly sensitive to this interaction as determined in the <xref ref-type="sec" rid="s3-3-4-1">Section 3.3.4.1</xref>. The adjusted kinetic value for this interaction was taken as 0.1. The parameter scanning results in <xref ref-type="fig" rid="F8">Figure 8A</xref> show the perfect conjunction of survival and apoptotic curves at the value 0.1. However, the change in parameter value profoundly affects the homeostatic state of the model and causes a profound increase in the relative difference with increasing or decreasing kinetic values.<disp-formula id="e17">
<mml:math id="m19">
<mml:mi>P</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>C</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.1</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>a</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>C</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>D</mml:mi>
</mml:math>
<label>(17)</label>
</disp-formula>
<disp-formula id="e18">
<mml:math id="m20">
<mml:mi>R</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>P</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mi>T</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>F</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>R</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>R</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>D</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.01</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>P</mml:mi>
</mml:math>
<label>(18)</label>
</disp-formula>
<disp-formula id="e19">
<mml:math id="m21">
<mml:mi>a</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>E</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>K</mml:mi>
<mml:mspace width="0.17em"/>
<mml:mo>&#x2b;</mml:mo>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mo>&#x2192;</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>0.01</mml:mn>
<mml:mfenced open="(" close=")">
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mover>
</mml:mrow>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mspace width="0.17em"/>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>D</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
</mml:math>
<label>(19)</label>
</disp-formula>
</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Paramater scanning of Interactions having huge impact on the Neuronal Survival and Apoptosis- <bold>(A)</bold> Paramater scanning of Interaction 27 (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref>) representing Cathepsin D activation. <bold>(B)</bold> Paramater scanning for Interaction 49 (<xref ref-type="disp-formula" rid="e18">Eq. 18</xref>) representing RIP recruitment. <bold>(C)</bold> Paramater scanning for Interaction 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>) representing ERK-mediated Cell Death. The increasing parameter value of the interactions representing Cathepsin D activation and ERK-mediated Cell Death over the range of 0&#x2013;0.2 enhances neuronal apoptosis and decreases neuronal survival. However, the increasing parameter value of the interactions representing recruitment of RIP only enhances neuronal apoptosis without impacting neuronal survival.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g008.tif"/>
</fig>
<p>The sensitivity analysis results in <xref ref-type="sec" rid="s3-3-4-1">Section 3.3.4.1</xref> determined the high influence of RIP recruitment on neuronal apoptosis. The recruitment of RIP <italic>via</italic> TRADD is given by interaction 49 (<xref ref-type="disp-formula" rid="e18">Eq. 18</xref>) with adjusted kinetics of 0.01. The parameter scanning results for this interaction, as given by <xref ref-type="fig" rid="F8">Figure 8B</xref>, clearly show that an increase in parameter value causes an increase in neuronal apoptosis. Moreover, the higher kinetic values also inflate the relative difference between survival and apoptotic curves. ERK signaling cascade contributes both to neuronal survival as well as in apoptosis. The ERK-mediated neuronal apoptosis is indicated by interaction 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>) with the adjusted kinetic value of 0.01. The parameter scanning results for this interaction as given by <xref ref-type="fig" rid="F8">Figure 8C</xref> are following the sensitivity results as described in <xref ref-type="sec" rid="s3-3-4-1">Section 3.3.4.1</xref>. The increasing parameter value increases apoptosis and decreases neuronal survival, thus, leading to a large relative difference among them with a rate increase. <xref ref-type="fig" rid="F8">Figures 8A&#x2013;C</xref> show parameter scanning for interactions 17, 18 and 19 respectively. The sensitivity analysis results as discussed in <xref ref-type="sec" rid="s3-3-4-1">Section 3.3.4.1</xref> revealed their high influence on neuronal death and survival. The parameter scanning curves for these interactions further conform to their significance as the change in their values causes drastic effects on neuronal survival and death.</p>
</sec>
<sec id="s3-3-4-3">
<title>3.3.4.3 Entities vs. entities</title>
<p>Similarly, to study the influence of model entities concentrations over the other entities, the sensitivity values of model entities towards other entities are calculated (given in the <xref ref-type="sec" rid="s11">Supplementary Material Section 7</xref>). The results (as evident from <xref ref-type="fig" rid="F7">Figure 7B</xref>), revealed the significant sensitivity of neuronal death towards recruitRIP, RIP_RAIDD, actCASP8, actCASP2, actCASP3and9, cytochrome C, actBID and actCathepsinD. Moreover, neuronal survival was found more sensitive to actCAPK, RasGTP, actAKT, actERK, actMEK, actRAF. Apart from observing the sensitivities of neuronal death and survival against model parameters and entities, we also noticed a significant impact of model entities over the other entities. NF<italic>&#x3ba;</italic>B, IKK, and NIK were found highly sensitive to TRADD_TRAF2 complex with the sensitivity values of 45.39, 46.84, and 48.33, respectively. Moreover, SMase enzyme and PKC showed high sensitivities against TNFR_FAN with the values of 49.04 and 47.4, respectively.</p>
</sec>
</sec>
</sec>
<sec id="s3-4">
<title>3.4 Dose estimation of drug and its response</title>
<sec id="s3-4-1">
<title>3.4.1 Effect of etanercept</title>
<p>The simulation result shows that Etanercept doesn&#x2019;t produce a fierce effect on neuronal apoptosis for the current model (<xref ref-type="fig" rid="F9">Figure 9A</xref>). The scanning result of Etanercept over a concentration range of 0&#x2013;100 shown in <xref ref-type="fig" rid="F9">Figure 9B</xref> further fortifies the fact of little efficacy of Etanercept for the current model. Moreover, neuronal survival remains completely unaffected by the application of Etanercept. Curves in <xref ref-type="fig" rid="F9">Figures 9C&#x2013;E</xref> show the repeated dosage effects of Etanercept with different start times and amounts as mentioned in <xref ref-type="table" rid="T4">Table 4</xref>. The outcomes clearly indicate the accumulation of Etanercept with increasing concentrations without prominently disturbing the balanced state of neurons.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>
<bold>(A)</bold> Simulation showing effect of Etanercept on Neuronal Survival and Death. <bold>(B)</bold> Scanning of Etanercept performed over range 0&#x2013;100 shows only minor decrease in cell death. <bold>(C&#x2013;G)</bold> Figures c to g represent the dosage graphs for Etanercept according to <xref ref-type="table" rid="T4">Table 4</xref>. Dosages <bold>(C&#x2013;G)</bold> have no obvious effect on neuronal death and survival.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g009.tif"/>
</fig>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Application of Drugs using Repeat Dose.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Drugs</th>
<th align="left">Doses</th>
<th align="left">Start Time</th>
<th align="left">Amount</th>
<th align="left">Rate (k)</th>
<th align="left">Interval</th>
<th align="left">Repeat Count</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="left">Etanercept (10<sup>&#x2013;12</sup>) (Chembl1201572)</td>
<td align="left">Dose 1</td>
<td align="left">0</td>
<td align="left">0.1</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 2</td>
<td align="left">0.1</td>
<td align="left">0.2</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 3</td>
<td align="left">0.2</td>
<td align="left">0.4</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 4</td>
<td align="left">0.3</td>
<td align="left">0.6</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 5</td>
<td align="left">0.4</td>
<td align="left">0.8</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td rowspan="5" align="left">Nivocasan (Chembl2105721)</td>
<td align="left">Dose 1</td>
<td align="left">0</td>
<td align="left">0.1</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 2</td>
<td align="left">0.1</td>
<td align="left">0.2</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 3</td>
<td align="left">0.2</td>
<td align="left">0.4</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 4</td>
<td align="left">0.3</td>
<td align="left">0.6</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 5</td>
<td align="left">0.4</td>
<td align="left">0.8</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td rowspan="5" align="left">Scyphostatin (10<sup>&#x2013;6</sup>) (Chembl418376)</td>
<td align="left">Dose 1</td>
<td align="left">0</td>
<td align="left">0.1</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 2</td>
<td align="left">0.1</td>
<td align="left">0.2</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 3</td>
<td align="left">0.2</td>
<td align="left">0.4</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 4</td>
<td align="left">0.3</td>
<td align="left">0.6</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Dose 5</td>
<td align="left">0.4</td>
<td align="left">0.8</td>
<td align="left">1</td>
<td align="left">5</td>
<td align="left">3</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-4-2">
<title>3.4.2 Effect of nivocasan</title>
<p>As reported earlier in <xref ref-type="sec" rid="s3-3-4-3">Section 3.3.4.3</xref>, the sensitivity analysis showed the high significance of caspase 8 and caspase 9 towards neuronal apoptosis. We repositioned the Nivocasan to the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model to analyze the model&#x2019;s response towards caspase inhibitor. The simple simulation of model treated with Nivocasan with the initial amount 3 is given by <xref ref-type="fig" rid="F10">Figure 10A</xref>. The caspase 8 and caspase 9 inhibition due to the application of Nivocasan results in lowering neuronal apoptosis with the difference of more than two folds.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>
<bold>(A)</bold> Simulation showing effect of Nivocasan on Neuronal Survival and Death. <bold>(B)</bold> Scanning of Nivocasan. <bold>(C&#x2013;G)</bold> Figures c to g represent the dosage graphs for the Nivocasan as according to <xref ref-type="table" rid="T4">Table 4</xref>. Dosages <bold>(C&#x2013;G)</bold> show obvious effect on neuronal death.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g010.tif"/>
</fig>
<p>Scanning was also performed for Nivocasan over the concentration range of 0&#x2013;100. The corresponding results in <xref ref-type="fig" rid="F10">Figure 10B</xref> show that increasing the amount of Nivocasan reduced the apoptotic mechanism up to a minimum point. The highest effect of Nivocasan is achieved for concentration 10 where apoptosis is minimum with the relative difference of about 2.5 folds. The application of repeated dosage of Nivocasan as according to the <xref ref-type="table" rid="T4">Table 4</xref> produces graphs as given by <xref ref-type="fig" rid="F10">Figures 10C&#x2013;G</xref>. It is evident from the results that the effective dosage of Nivocasan can reduce neuronal apoptosis by creating a relative difference of about 2.5 folds between neuronal survival and neuronal death.</p>
</sec>
<sec id="s3-4-3">
<title>3.4.3 Effect of scyphostatin</title>
<p>
<xref ref-type="fig" rid="F11">Figure 11A</xref> indicates that Scyphostatin fails to disturb the hypothesized equilibrium state of the model. The curves in <xref ref-type="fig" rid="F11">Figure 11B</xref> show the scanning effect of Scyphostatin from concentration 0&#x2013;100 for TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway model. It is evident from the results that increasing the concentration of drugs lowers both cell survival and cell death without affecting the overall homeostasis. The results of repeated dosages of Scyphostatin according to <xref ref-type="table" rid="T4">Table 4</xref> four are given by <xref ref-type="fig" rid="F11">Figures 11C&#x2013;G</xref>. The results follow the speculations derived from Scyphostatin&#x2019;s simulation and scanning. The model remains unaffected from repeat dosages with different starting times and amounts and retains its balanced state.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>
<bold>(A)</bold> Simulation showing effect of Scyphostatin on Neuronal Survival and Death. <bold>(B)</bold> Scanning of Scyphostatin. <bold>(C&#x2013;G)</bold> Figures c to g represent the dosage graphs for Scyphostatin according to <xref ref-type="table" rid="T4">Table 4</xref>. Dosage <bold>(C&#x2013;G)</bold> have no obvious effect on neuronal death and survival.</p>
</caption>
<graphic xlink:href="fphys-13-872421-g011.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec id="s4">
<title>4 Discussion</title>
<p>The growing number of individuals affected by neurodegenerative disorders worldwide was a reason to focus and study diversified aspects of neurological diseases using a modeling approach. The severity of nearly all neuropathological diseases in AD, PD, and MS eventually leads to raised levels of TNF-<italic>&#x3b1;</italic> owing to enhanced glial cell production (<xref ref-type="bibr" rid="B61">Sharma et al., 2012</xref>; <xref ref-type="bibr" rid="B57">Sawada et al., 2006</xref>; <xref ref-type="bibr" rid="B76">Xu et al., 2015</xref>). The modeling of the sphingolipid metabolic pathway in association with TNF-<italic>&#x3b1;</italic> signaling provides a novel viewpoint on the behavior of various proteins, enzymes, and sphingolipids under homeostatic and pathological circumstances of neurons. Like sphingolipids, an up-regulated TNF-<italic>&#x3b1;</italic> expression has also been associated with the causation as well as the progression of several neurodegenerative diseases of the central nervous system (CNS) (<xref ref-type="bibr" rid="B17">Chitnis and Weiner, 2017</xref>). TNF-<italic>&#x3b1;</italic>, in alliance with its receptors, instigates the number of signaling pathways, including the sphingomyelin pathway (<xref ref-type="bibr" rid="B50">Olmos and Llad&#xf3;, 2014</xref>). The literature studies in the subsequent part of discussion show the implication of cytokines and sphingolipid metabolites in numerous neuro-pathologies, making them robust targets for system-level studies.</p>
<p>In this study, the representational model of the TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling system is modeled in Simbiology, which includes 73 entities and 51 interactions, to examine the linkage and interactions holistically. We built the model integrating data from the literature and KEGG, and the input concentrations of model entities were calculated using microarray data analysis. The kinetic rates of the interactions were set between the range 0.01&#x2013;0.1 such that the system could depict the homeostatic balanced state of neuronal survival and apoptotic mechanisms. The values of kinetic parameters for model&#x2019;s interactions were adjusted due to lack of kinetic values from literature. Therefore, relative time unit &#x201c;RTU&#x201d; was employed as a unit of time rather than the specific units. The simulation run of the model explicitly manifested the time and concentration of model entities during their recruitment or activation. Moreover, the simulation enabled us to track the minor details of even minute changes in entities concentrations over time. <xref ref-type="fig" rid="F5">Figure 5</xref> showed the hypothesized stable (balanced) state of TNF-<italic>&#x3b1;</italic> mediated sphingomyelin and related signaling pathways exhibited by neurons during normal circumstances.</p>
<p>The network analysis of the model using Cytoscape tool reveals the system&#x2019;s essential components (adaptor proteins, enzymes, and chemicals) based on their betweenness and closeness centralities. The betweenness centralities of model entities were found in the following descending order: ceramide (0.078) <inline-formula id="inf3">
<mml:math id="m22">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> actSMase (0.051) <inline-formula id="inf4">
<mml:math id="m23">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> GiCoupled Receptor (0.031) <inline-formula id="inf5">
<mml:math id="m24">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> actS1PR (0.03) <inline-formula id="inf6">
<mml:math id="m25">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> sphingosine (0.0298) <inline-formula id="inf7">
<mml:math id="m26">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> recruitFADD (0.0292) <inline-formula id="inf8">
<mml:math id="m27">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> S1P(0.028) <inline-formula id="inf9">
<mml:math id="m28">
<mml:mo>&#x3c;</mml:mo>
</mml:math>
</inline-formula> TNFR_TRADD (0.023); evincing the high importance of ceramide among all other entities. It can be associated with the elevated levels of ceramide in the brain samples from patients affected by AD and other neurodegenerative disorders contributing to their pathophysiology (<xref ref-type="bibr" rid="B25">Filippov et al., 2012</xref>; <xref ref-type="bibr" rid="B2">Alessenko and Albi, 2020</xref>). The sphingolipids including ceramide, sphingomyelinase, and sphingosine with high betweeness centralities serve as prognostic biomarkers of neurodegeneration because of their increased levels in the AD brain (<xref ref-type="bibr" rid="B70">van Kruining et al., 2020</xref>). Moreover, the closeness centrality measure manifested the high closeness of actCASP2, actCASP8, cIAP2, actCAPP, actCASP 3and9, actAKT, actERK, cytochrome C, RIP_RAIDD, actNFkB, CAPP, recruitAKT, and PDK1 among all other entities of the model with closeness centrality values ranging from 1 to 0.63. <xref ref-type="bibr" rid="B45">Matsui et al. (2006)</xref> provided evidences of literature studies showing an increased activation of caspases 3, 8, and 9 in AD brain samples (<xref ref-type="bibr" rid="B45">Matsui et al., 2006</xref>).</p>
<p>The scanning results of elements with high betweenness centrality values further signified them being the most crucial components in the TNF-<italic>&#x3b1;</italic>-mediated sphingomyelin signaling pathway. The high impact of recruitFADD and TNFR_TRADD was observed on the neuronal apoptosis, whereas Gi-coupled receptor, actS1PR, Sphingosine, and S1P were found to produce a high influence on neuronal survival. <xref ref-type="bibr" rid="B78">Zhao et al. (2003)</xref> reported the elevated levels of both TNF-<italic>&#x3b1;</italic> and TRADD (being proapototic elements) in AD patients (<xref ref-type="bibr" rid="B78">Zhao et al., 2003</xref>). However, the current study inferred the dual role of ceramide, both on neuronal survival and apoptosis (<xref ref-type="bibr" rid="B53">Posse de Chaves, 2006</xref>), which suggests the multipotential function of ceramide both in neuronal survival and apoptosis (<xref ref-type="bibr" rid="B68">Toman et al., 2000</xref>). Neuronal apoptosis was more affected by the recruitFADD with a betweenness value of 0.0292 when compared to TNFR_TRADD (betweenness value 0.023). It suggests the increased levels of FADD protein that occur in the midbrain of PD patients. (<xref ref-type="bibr" rid="B27">Gorman, 2008</xref>). Moreover, <xref ref-type="bibr" rid="B24">Ferguson et al. (2020)</xref> found the high levels of FADD in the post-mortem brain tissue from the BA21 region of African Americans affected by AD (<xref ref-type="bibr" rid="B24">Ferguson et al., 2020</xref>). Also, <xref ref-type="bibr" rid="B74">Wu et al. (2005)</xref> presented the first demonstration of enhanced FADD expression in the AD brain (<xref ref-type="bibr" rid="B74">Wu et al., 2005</xref>). It can also be observed that among the Gi-coupled receptor, actS1PR, sphingosine, and S1P, the increased activation of the Gi-coupled receptor highly influenced neuronal survival. The increasing concentrations of actCASP2, actCASP8, actCASP 3and9, cytochrome C, and RIP_RAIDD with the high closeness centrality values appeared as entities chiefly affecting the neuronal apoptosis. The scanning of actCASP2, actCASP8, and actCASP3and9 showed their profound influence on neuronal apoptosis due to the high centrality value.</p>
<p>The parameter scanning allowed comparison of kinetic parameters used in the current study with some of kinetic values according to the literature (<xref ref-type="bibr" rid="B18">Cho et al., 2003</xref>). The variations among these kinetics were marked bearable as they lied within tolerable ranges of variations and showed no drastic effects on the model. Scanning was done for the kinetic parameter values for interactions 1 (<xref ref-type="disp-formula" rid="e8">Eq. 8</xref>), 2 (<xref ref-type="disp-formula" rid="e9">Eq. 9</xref>), 7 (<xref ref-type="disp-formula" rid="e11">Eq. 11</xref>), 8 (<xref ref-type="disp-formula" rid="e10">Eq. 10</xref>), 9 (<xref ref-type="disp-formula" rid="e12">Eq. 12</xref>), 12 (<xref ref-type="disp-formula" rid="e13">Eq. 13</xref>), 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>), 31 (<xref ref-type="disp-formula" rid="e15">Eq. 15</xref>) and 38 (<xref ref-type="disp-formula" rid="e16">Eq. 16</xref>) and compared with some known parameter kinetics to determine their effect on the homeostatic state of the model. Parameter scanning over the range 0&#x2013;0.2 of the mentioned interactions showed that kinetic rate parameters governing TNF_TNFR formation, recruitment of RAIDD, TNFR-TRADD formation, recruitment of FADD, TRADD_TRAF2 formation, TNFR_FAN association, S1PR activation, and recruitment of AKT only cause minor alterations in the balanced state of the system over the given range. The exceprional behavior of NF<italic>&#x3ba;</italic>B can be attributed to its contribution in promoting cell survival <italic>via</italic> its inhibitory action on caspase 8.</p>
<p>Sensitivity analysis allowed us to determine the effects of all the interaction parameters (kinetics) on the model entities, and also among the entities themselves. Sensitivity analysis of entities versus parameters indicated the high impact of interaction 1 representing TNF-<italic>&#x3b1;</italic> binding with TNFR and interaction 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>) representing TNFR_FAN association over SMase enzyme with the sensitivity values of 613.7 and 657.6 (over the scale ranging from 0 to 700), respectively. The Jurkat T lymphocytes showed a significant increase in the activity of acidic SMase and a minor increase in the activity of neutral SMase (NSMase) when exposed to TNF-<italic>&#x3b1;</italic> (for 5&#xa0;min and 7&#xa0;h, respectively) due to enhanced TNF-<italic>&#x3b1;</italic>/TNFR1 binding (<xref ref-type="bibr" rid="B19">Church et al., 2005</xref>). Moreover, the FAN constitutively binds with neutral sphingomyelinase activation domain (NSD) of TNFR1 and triggers activation of NSMase (<xref ref-type="bibr" rid="B47">Montfort et al., 2010</xref>). We also witnessed the high impact of interaction 15 (<xref ref-type="disp-formula" rid="e14">Eq. 14</xref>) on PKC with a sensitivity value of 636.3. BID and CASP 3and9 were found highly sensitive to interaction 27 (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref>) (representing ceramide triggered activation of cathepsin D) with values 682 and 641.6, respectively. This infers the role of ceramide induced activation of cathepsin D to form truncated BID (tBID, referred as actBID in model) from BID <xref ref-type="bibr" rid="B54">Poulaki and Giannouli (2022)</xref>. Neuronal survival was found sensitive to interaction 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>), interaction 40, interaction 18, interaction 43 and interaction 34 of the model (shown in the <xref ref-type="fig" rid="F7">Figure 7A</xref> and <xref ref-type="sec" rid="s11">Supplementary Material Section 6</xref>) with the sensitivity values 483.3, 302.1, 295.7, 234.7, and 209.6, respectively. These interactions represent ERK-mediated neuronal apoptosis, the CAPP-mediated inhibition of AKT, CAPK activation, ERK-mediated neuronal survival, and conversion of RasGTP to RasGDP, respectively. <xref ref-type="bibr" rid="B26">Finegan et al. (2009)</xref> provided the genetic evidence for the involvement of ERK5 in regulating neuronal survival (<xref ref-type="bibr" rid="B26">Finegan et al., 2009</xref>). However, neuronal death was most affected by interaction 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>), interaction 27 (17), interaction 49 (18) and interaction 28 representing ERK-mediated neuronal apoptosis, ceramide triggered activation of cathepsin D, recruitment of RIP <italic>via</italic> TNFR_TRADD and caspase 3,9 activated cell death with sensitivity values 669.7, 471.4, 418.9 and 220.5 respectively. Sensitivity analysis of parameters versus entities showed highly influence of interactions governing cathepsin D activation (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref>), recruitment of RIP (<xref ref-type="disp-formula" rid="e18">Eq. 18</xref>) and ERK-mediated neuronal death (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>) on neuronal apoptosis. In the literature, we have evidence of the dual role of ERK signaling pathway in neuronal survival and apoptosis (<xref ref-type="bibr" rid="B42">Li et al., 2014</xref>). The parameter scanning results of interactions 27 (<xref ref-type="disp-formula" rid="e17">Eq. 17</xref>), 49 (<xref ref-type="disp-formula" rid="e18">Eq. 18</xref>) and 51 (<xref ref-type="disp-formula" rid="e19">Eq. 19</xref>) were perfectly in accordance with their sensitivity effect on apoptosis and survival.</p>
<p>Finally, the efficacy of different FDA-approved drugs was determined by analyzing the response of the sphingomyelin signaling pathway model towards different drugs&#x2019; dosages. The appropriate drugs were selected based on their applicability and effectiveness for the relevant targets in the current model. Etanercept, Nivocasan, and Scyphostatin were among the drugs whose dosages were examined. Each drug&#x2019;s results and effects were tracked by scanning and repeated dosing. It was found that Etanercept and Scyphostatin had no effect on the model&#x2019;s equilibrium, and led to their accumulation. However, Nivocasan&#x2019;s irreversible inhibitory actions on caspase 8 and caspase 9 significantly reduced neuronal apoptosis to a large degree (<xref ref-type="bibr" rid="B75">Xie et al., 2020</xref>). Caspase 8 is an important mediator of neuronal apoptosis during neurodegenerative diseases (<xref ref-type="bibr" rid="B77">Zhang et al., 2020</xref>), whereas <xref ref-type="bibr" rid="B10">Blandini et al., (2006)</xref> reported enhanced activity of caspase 9 in PD patients (<xref ref-type="bibr" rid="B10">Blandini et al., 2006</xref>). It is worth mentioning that caspases 8 and 9 showed high closeness centrality <italic>via</italic> network analysis, manifesting their importance in TNF-<italic>&#x3b1;</italic> mediated sphingomyelin signaling pathway. <xref ref-type="bibr" rid="B7">Avrutsky and Troy (2021)</xref> examined the role of caspase 9 as a multimodal therapeutic target for a range of diseases including AD (<xref ref-type="bibr" rid="B7">Avrutsky and Troy, 2021</xref>). Hence, the significance of Nivocasan was pronounced due to its applicability on caspase 8 and caspase 9.</p>
<p>As mentioned earlier, different neuropathologies including immune disease, trauma, and inflammation may lead to rapid and irreversible neurological damage. Different pharmacological treatments have been formulated and applied for the aforementioned neurological disorders. Etanercept, a TNF antagonist is used as a TNF blocker in order to minimize the neurological damage mediated by TNF-dependent processes (<xref ref-type="bibr" rid="B36">Kondziella and Waldemar, 2017</xref>). <xref ref-type="fig" rid="F9">Figure 9</xref> and <xref ref-type="fig" rid="F11">Figure 11</xref> show the response of the model towards the drugs Etanercept and Scyphostatin. The simulation result shows that Etanercept doesn&#x2019;t produce any apparent reduction in neuronal apoptosis for the current model. Likewise, the drug Scyphostatin fails to show any prominent effect on neuronal apoptosis or survival. On the other hand, a precise concentration of Nivocasan produces a magnificent curtailment in neuronal apoptosis.</p>
</sec>
<sec id="s5">
<title>5 Conclusion and future perspectives</title>
<p>Neurological disorders are the leading cause of disabilities and deaths worldwide. Most of them are neurodegenerative and are responsible for initiating neuroinflammatory responses. The prevailing conditions of neurological injuries induce sustained neuroinflammation, which ultimately leads to neuronal loss and death. The formulation of common therapeutic strategies for all neurodegenerative disorders at the later inflammatory stages can prevent the most damaging state of neuronal loss. The integration of common neuroinflammatory responses with the sphingolipid signaling pathway, and their quantitative analysis <italic>via</italic> computational modeling approach, provided a broad spectrum of devising therapeutic targets. The findings identified the number of caspases (CASP2, CASP8, and CASP9) and sphingolipids (S1P) as potent proteins having therapeutic significance at subsequent stages of the disease. Moreover, the drug dosage analysis evaluated the efficacy of three drugs, i.e., Etanercept, Nivocasan, and Scyphostatin, at the level of neuroinflammatory responses.</p>
<p>The application of Etanercept and Scyphostatin with varying dosages failed to suppress neuronal apoptosis, or in other words, did not disturb the homeostatic balanced state of neurons. These results manifested that repurposing of the two drugs was impracticable at later stages of neuroinflammation. However, the drug dosage analysis indicated Nivocasan&#x2019;s exertion of the inhibitory mechanism at caspase 8 and caspase 9, which significantly altered the system homeostasis. It shows that the neuronal homeostatic state is prone to transmute at the later stages of inflammation when encountered with caspase 8 and caspase 9 inhibitors. The current study (model generated and analyzed using AD data) can be extended to other neurodegenerative diseases like PD and MS to analyze the effects of various entities and interaction parameters and formulate effective therapeutics at their furthest levels.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>Publicly available datasets were analyzed in this study. This data can be found here: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36980">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc&#x3d;GSE36980</ext-link>.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>All authors participated in the design of this study, analyzed the results, read, revised and approved the final manuscript. SB constructed the mathematical model, perform simulations and wrote the initial draft of the manuscript. RNP and MN contributed in submission of reviewer response.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>National University of Sciences and Technology (NUST), will pay the publication fee for this article.</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphys.2022.872421/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphys.2022.872421/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet2.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM2" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="thesis">
<person-group person-group-type="author">
<name>
<surname>Adriaenssens</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>Implementation of carboxylate isosteres to improve inflammatory caspase inhibitors</article-title>,&#x201d; (<publisher-loc>Belgium</publisher-loc>: <publisher-name>University of Antwerp</publisher-name>). <comment>PhD thesis</comment>. </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alessenko</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Albi</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Exploring sphingolipid implications in neurodegeneration</article-title>. <source>Front. Neurol.</source> <volume>11</volume>, <fpage>437</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2020.00437</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Vasquez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Hannun</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Voit</surname>
<given-names>E. O.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Integration of kinetic information on yeast sphingolipid metabolism in dynamical pathway models</article-title>. <source>J. Theor. Biol.</source> <volume>226</volume> (<issue>3</issue>), <fpage>265</fpage>&#x2013;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2003.08.010</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Vasquez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Voit</surname>
<given-names>E. O.</given-names>
</name>
<name>
<surname>Hannun</surname>
<given-names>Y. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Coordination of the dynamics of yeast sphingolipid metabolism during the diauxic shift</article-title>. <source>Theor. Biol. Med. Model.</source> <volume>4</volume> (<issue>1</issue>), <fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/1742-4682-4-42</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<collab>Alzheimer&#x2019;s Association</collab> (<year>2021</year>). <article-title>alzheimer&#x2019;s disease facts and figures</article-title>. <source>Alzheimer&#x2019;s Dementia</source> <volume>17</volume> (<issue>3</issue>), <fpage>327</fpage>&#x2013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12328</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avrutsky</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>Troy</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Caspase-9: A multimodal therapeutic target with diverse cellular expression in human disease</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>701301</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.701301</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baratz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Rubovitch</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>J. H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Transiently lowering tumor necrosis factor-<italic>&#x3b1;</italic> synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice</article-title>. <source>J. Neuroinflammation</source> <volume>12</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1186/s12974-015-0237-4</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basham</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Glial cells &#x26; its function</article-title>. <source>J. Neurology Neurophysiology</source> <volume>12</volume> (<issue>3</issue>), <fpage>1</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.35248/21559562.20.12.523</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blandini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sinforiani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pacchetti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Samuele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bazzini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zangaglia</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Peripheral proteasome and caspase activity in Parkinson disease and alzheimer disease</article-title>. <source>Neurology</source> <volume>66</volume> (<issue>4</issue>), <fpage>529</fpage>&#x2013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000198511.09968.b3</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buccoliero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Futerman</surname>
<given-names>A. H.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The roles of ceramide and complex sphingolipids in neuronal cell function</article-title>. <source>Pharmacol. Res.</source> <volume>47</volume> (<issue>5</issue>), <fpage>409</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1016/s1043-6618(03)00049-5</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabal-Hierro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lazo</surname>
<given-names>P. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Signal transduction by tumor necrosis factor receptors</article-title>. <source>Cell. Signal.</source> <volume>24</volume> (<issue>6</issue>), <fpage>1297</fpage>&#x2013;<lpage>1305</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2012.02.006</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carniglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ram&#xed;rez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Saba</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Juan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>Carla</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases</article-title>. <source>Mediat. Inflamm.</source> <volume>2017</volume>, <fpage>5048616</fpage>. <pub-id pub-id-type="doi">10.1155/2017/5048616</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chadwick</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Keselman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Maudsley</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Targeting tnf-<italic>&#x3b1;</italic> receptors fo rneurotherapeutics</article-title>. <source>Trends Neurosci.</source> <volume>31</volume> (<issue>10</issue>), <fpage>504</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2008.07.005</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.-W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.-J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Role of neuroinflammation in neurodegenerative diseases (Review)</article-title>. <source>Mol. Med. Rep.</source> <volume>13</volume> (<issue>4</issue>), <fpage>3391</fpage>&#x2013;<lpage>3396</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.4948</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chignola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Farina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Del Fabbro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milotti</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Balance between cell survival and death: A minimal quantitative model of tumor necrosis factor alpha cytotoxicity</article-title>. <comment>
<italic>arXiv preprint arXiv:0905.4396</italic>
</comment>, <year>2009</year>. </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chitnis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>H. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cns inflammation and neurodegeneration</article-title>. <source>J. Clin. Invest.</source> <volume>127</volume> (<issue>10</issue>), <fpage>3577</fpage>&#x2013;<lpage>3587</lpage>. <pub-id pub-id-type="doi">10.1172/JCI90609</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wolkenhauer</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Experimental design in systems biology, based on parameter sensitivity analysis using a Monte Carlo method: A case study for the tnf<italic>&#x3b1;</italic>-mediated nf-<italic>&#x3ba;</italic> b signal transduction pathway</article-title>. <source>Simulation</source> <volume>79</volume> (<issue>12</issue>), <fpage>726</fpage>&#x2013;<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1177/0037549703040943</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Church</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Hessler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Goodall</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Rider</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Workman</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Vignali</surname>
<given-names>D. A. A.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Tnfr1-induced sphingomyelinase activation modulates tcr signaling by impairing store-operated ca2&#x2b; influx</article-title>. <source>J. Leukoc. Biol.</source> <volume>78</volume> (<issue>1</issue>), <fpage>266</fpage>&#x2013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.1003456</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cutsuridis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moustafa</surname>
<given-names>A. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Computational models of alzheimer&#x2019;s disease</article-title>. <source>Scholarpedia</source> <volume>12</volume> (<issue>1</issue>), <fpage>32144</fpage>. <pub-id pub-id-type="doi">10.4249/scholarpedia.32144</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kamada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P. H.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Akt/gsk3<italic>&#x3b2;</italic> survival signaling is involved in acute brain injury after subarachnoid hemorrhage in rats</article-title>. <source>Stroke</source> <volume>37</volume> (<issue>8</issue>), <fpage>2140</fpage>&#x2013;<lpage>2146</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000229888.55078.72</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Eriksen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kirstine Stark</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pakkenberg</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2009</year>). &#x201c;<article-title>Age and Parkinson&#x2019;s disease-related neuronal death in the substantia nigra pars compacta</article-title>,&#x201d; in <source>Birth, life and death of dopaminergic neurons in the substantia nigra</source> (<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>203</fpage>&#x2013;<lpage>213</lpage>. </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Aducanumab as a novel treatment for alzheimer&#x2019;s disease: A decade of hope, controversies, and the future</article-title>. <source>Cureus</source> <volume>13</volume> (<issue>8</issue>), <fpage>e17591</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.17591</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Panos</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Increased inflammation in ba21 brain tissue from african americans with alzheimer&#x2019;s disease</article-title>. <source>Metab. Brain Dis.</source> <volume>35</volume> (<issue>1</issue>), <fpage>121</fpage>&#x2013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1007/s11011-019-00512-2</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filippov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>H. V.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>W. M.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Increased ceramide in brains with alzheimer&#x2019;s and other neurodegenerative diseases</article-title>. <source>J. Alzheimers Dis.</source> <volume>29</volume> (<issue>3</issue>), <fpage>537</fpage>&#x2013;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2011-111202</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finegan</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E.-J.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Tournier</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Regulation of neuronal survival by the extracellular signal-regulated protein kinase 5</article-title>. <source>Cell Death Differ.</source> <volume>16</volume> (<issue>5</issue>), <fpage>674</fpage>&#x2013;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2008.193</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorman</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Neuronal cell death in neurodegenerative diseases: Recurring themes around protein handling</article-title>. <source>J. Cell. Mol. Med.</source> <volume>12</volume> (<issue>6</issue>), <fpage>2263</fpage>&#x2013;<lpage>2280</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00402.x</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Eils</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schlesner</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source> <volume>32</volume> (<issue>18</issue>), <fpage>2847</fpage>&#x2013;<lpage>2849</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haque</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Levey</surname>
<given-names>A. I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Alzheimer&#x2019;s disease: A clinical perspective and future nonhuman primate research opportunities</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>116</volume> (<issue>52</issue>), <fpage>26224</fpage>&#x2013;<lpage>26229</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1912954116</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haughey</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Bandaru</surname>
<given-names>V. V. R.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>M. P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Roles for dysfunctional sphingolipid metabolism in alzheimer&#x2019;s disease neuropathogenesis</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1801</volume> (<issue>8</issue>), <fpage>878</fpage>&#x2013;<lpage>886</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2010.05.003</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Microglia in Parkinson&#x2019;s disease</article-title>. <source>Neuroglia Neurodegener. Dis.</source>, <volume>1175</volume>, <fpage>35</fpage>&#x2013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-13-9913-8_13</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Kegg: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res.</source> <volume>28</volume> (<issue>1</issue>), <fpage>27</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaus</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reisenauer</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>An end to end workflow for differential gene expression using affymetrix microarrays</article-title>. <source>F1000Res.</source> <volume>5</volume>, <fpage>1384</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.8967.1</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reisig</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2010</year>). <source>Modeling in systems biology: The petri net approach</source>, <volume>16</volume>. <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer Science &#x26; Business Media</publisher-name>. </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kole</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Annis</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Deshmukh</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Mature neurons: Equipped for survival</article-title>. <source>Cell Death Dis.</source> <volume>4</volume> (<issue>6</issue>), <fpage>e689</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.220</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Kondziella</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Waldemar</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>Treatment of neurological disorders</article-title>,&#x201d; in <source>Neurology at the bedside</source>, <publisher-name>Springer</publisher-name>, <publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>, <fpage>291</fpage>&#x2013;<lpage>327</lpage>. </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudelova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fleischmannova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adamova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Matalova</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Pharmacological caspase inhibitors: Research towards therapeutic perspectives</article-title>. <source>J. Physiol. Pharmacol.</source> <volume>66</volume> (<issue>4</issue>), <fpage>473</fpage>&#x2013;<lpage>482</lpage>. </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ekavalli</surname>
</name>
</person-group> (<year>2015</year>). <article-title>A review on Alzheimer&#x2019;s disease pathophysiology and its management: An update</article-title>. <source>Pharmacol. Rep.: PR</source> <volume>67</volume> (<issue>2</issue>), <fpage>195</fpage>&#x2013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2014.09.004</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>S.-H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes</article-title>. <source>Transl. Neurodegener.</source> <volume>9</volume> (<issue>1</issue>), <fpage>42</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1186/s40035-020-00221-2</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Yankee</surname>
<given-names>E. L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A review on Parkinson&#x2019;s disease treatment</article-title>. <source>Neuroimmunol. Neuroinflammation</source> <volume>8</volume>. <pub-id pub-id-type="doi">10.20517/2347-8659.2020.58</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Neuroprotective properties and therapeutic potential of bone marrow&#x2013;derived microglia in alzheimer&#x2019;s disease</article-title>. <source>Am. J. Alzheimers Dis. Other Demen.</source> <volume>35</volume>, <fpage>1533317520927169</fpage>. <pub-id pub-id-type="doi">10.1177/1533317520927169</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The dual role of erk signaling in the apoptosis of neurons</article-title>. <source>Front. Biosci.</source> <volume>19</volume> (<issue>19</issue>), <fpage>1411</fpage>&#x2013;<lpage>1417</lpage>. <pub-id pub-id-type="doi">10.2741/4291</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Simulating bioreaction processes based on simbiology</article-title>. <source>Jisuanji Yingyong yu Ruanjian</source> <volume>27</volume> (<issue>8</issue>), <fpage>212</fpage>&#x2013;<lpage>214</lpage>. </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malagarie-Cazenave</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andrieu-Abadie</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gouaz&#xe9;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tardy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cuvillier</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Sphingolipid signalling: Molecular basis and role in tnf-<italic>&#x3b1;</italic>-induced cell death</article-title>. <source>Expert Rev. Mol. Med.</source> <volume>4</volume> (<issue>28</issue>), <fpage>1</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1017/S146239940200546X</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ramasamy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fukumoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Frosch</surname>
<given-names>M. P.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Coordinated expression of caspase 8, 3 and 7 mrna in temporal cortex of alzheimer disease: Relationship to formic acid extractable a<italic>&#x3b2;</italic>42 levels</article-title>. <source>J. Neuropathol. Exp. Neurol.</source> <volume>65</volume> (<issue>5</issue>), <fpage>508</fpage>&#x2013;<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1097/01.jnen.0000229238.05748.12</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGinley</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Goldschmidt</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Rae-Grant</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diagnosis and treatment of multiple sclerosis: A review</article-title>. <source>Jama</source> <volume>325</volume> (<issue>8</issue>), <fpage>765</fpage>&#x2013;<lpage>779</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.26858</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montfort</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>P. G. P.</given-names>
</name>
<name>
<surname>Levade</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Benoist</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Fan (factor associated with neutral sphingomyelinase activation), a moonlighting protein in tnf-r1 signaling</article-title>. <source>J. Leukoc. Biol.</source> <volume>88</volume> (<issue>5</issue>), <fpage>897</fpage>&#x2013;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0410188</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Ghatan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Garden</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2003</year>). &#x201c;<article-title>Neuronal survival and cell death signaling pathways</article-title>,&#x201d; in <source>Molecular and cellular biology of neuroprotection in the CNS</source> (<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>41</fpage>&#x2013;<lpage>86</lpage>. </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukherjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>More alive than dead: Non-apoptotic roles for caspases in neuronal development, plasticity and disease</article-title>. <source>Cell Death Differ.</source> <volume>24</volume> (<issue>8</issue>), <fpage>1411</fpage>&#x2013;<lpage>1421</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.64</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olmos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Llad&#xf3;</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity</article-title>, <source>Mediat. Inflamm.</source>, <volume>2014</volume>, <fpage>861231</fpage>. <pub-id pub-id-type="doi">10.1155/2014/861231</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orozco</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Valderrama-Chaparro</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Pinilla-Monsalve</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Molina-Echeverry</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>P&#xe9;rez Casta&#xf1;o</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Ariza-Ara&#xfa;jo</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Parkinson&#x2019;s disease prevalence, age distribution and staging in Colombia</article-title>. <source>Neurol. Int.</source> <volume>12</volume> (<issue>1</issue>), <fpage>8401</fpage>&#x2013;<lpage>8414</lpage>. <pub-id pub-id-type="doi">10.4081/ni.2020.8401</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitsinos</surname>
<given-names>E. N.</given-names>
</name>
<name>
<surname>Veit</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Karaliota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rigou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Couladouros</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Giannis</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Synthesis and evaluation of three novel scyphostatin analogues as neutral sphingomyelinase inhibitors</article-title>. <source>ChemBioChem</source> <volume>4</volume> (<issue>11</issue>), <fpage>1223</fpage>&#x2013;<lpage>1225</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200300667</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Posse de Chaves</surname>
<given-names>E. I.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Sphingolipids in apoptosis, survival and regeneration in the nervous system</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1758</volume> (<issue>12</issue>), <fpage>1995</fpage>&#x2013;<lpage>2015</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.09.0182015</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giannouli</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mitochondrial lipids: From membrane organization to apoptotic facilitation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>7</issue>), <fpage>3738</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23073738</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rangamani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Survival and apoptotic pathways initiated by tnf-<italic>&#x3b1;</italic>: Modeling and predictions</article-title>. <source>Biotechnol. Bioeng.</source> <volume>97</volume> (<issue>5</issue>), <fpage>1216</fpage>&#x2013;<lpage>1229</lpage>. <pub-id pub-id-type="doi">10.1002/bit.21307</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chavez-Galan</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Transmembrane tnf and its receptors tnfr1 and tnfr2 in mycobacterial infections</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>11</issue>), <fpage>5461</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22115461</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nagatsu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Role of cytokines in inflammatory process in Parkinson&#x2019;s disease</article-title>. <source>J. Neural Transm. Suppl.</source> <volume>11</volume>, <fpage>373</fpage>&#x2013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-211-45295-0_57</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barbour</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guido</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Immunization with amyloid-<italic>&#x3b2;</italic> attenuates alzheimer-disease-like pathology in the pdapp mouse</article-title>. <source>Nature</source> <volume>400</volume> (<issue>6740</issue>), <fpage>173</fpage>&#x2013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1038/22124</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Futerman</surname>
<given-names>A. H.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Inhibition of sphingolipid synthesis, but not degradation, alters the rate of dendrite growth in cultured hippocampal neurons</article-title>. <source>Brain Res. Dev. Brain Res.</source> <volume>108</volume> (<issue>1-2</issue>), <fpage>125</fpage>&#x2013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-3806(98)00041-8</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>S&#xe9;gui</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cuvillier</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Adam-Klages</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Malagarie-Cazenave</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>L&#xe9;v&#xea;que</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Involvement of fan in tnf-induced apoptosis</article-title>. <source>J. Clin. Invest.</source> <volume>108</volume> (<issue>1</issue>), <fpage>143</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1172/JCI11498</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Guleria</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Tumor necrosis factor and alzheimer&#x2019;s disease: A cause and consequence relationship</article-title>. <source>Klinik Psikofarmakoloji B&#xfc;lteni-Bulletin Clin. Psychopharmacol.</source> <volume>22</volume> (<issue>1</issue>), <fpage>86</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.5455/bcp.20120112064639</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siciliano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trojano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Santangelo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Micco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tedeschi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Alessandro</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Fatigue in Parkinson&#x2019;s disease: A systematic review and meta-analysis</article-title>. <source>Mov. Disord.</source> <volume>33</volume> (<issue>11</issue>), <fpage>1712</fpage>&#x2013;<lpage>1723</lpage>. <pub-id pub-id-type="doi">10.1002/mds.27461</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegmund</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mauri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reichwein</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Fas-associated death domain protein (fadd) and caspase-8 mediate up-regulation of c-fos by fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (trail) <italic>via</italic> a flice inhibitory protein (flip)-regulated pathway</article-title>. <source>J. Biol. Chem.</source> <volume>276</volume> (<issue>35</issue>), <fpage>32585</fpage>&#x2013;<lpage>32590</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M100444200</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Banik</surname>
<given-names>N. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases</article-title>. <source>Brain Res. Bull.</source> <volume>87</volume> (<issue>1</issue>), <fpage>10</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2011.10.004</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Subhramanyam</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Dheen</surname>
<given-names>S. T.</given-names>
</name>
</person-group> (<year>2019</year>). &#x201c;<article-title>Microglia-mediated neuroinflammation in neurodegenerative diseases</article-title>,&#x201d; in <source>Seminars in cell &#x26; developmental biology</source> (<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <volume>94</volume>, <fpage>112</fpage>&#x2013;<lpage>120</lpage>. </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teitsdottir</surname>
<given-names>U. D.</given-names>
</name>
<name>
<surname>Halldorsson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rolfsson</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Jonsdottir</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Snaedal</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cerebrospinal fluid c18 ceramide associates with markers of alzheimer&#x2019;s disease and inflammation at the pre-and early stages of dementia</article-title>. <source>J. Alzheimers Dis.</source> <volume>81</volume> (<issue>1</issue>), <fpage>231</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-200964</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="patent">
<person-group person-group-type="author">
<name>
<surname>Tobinick</surname>
<given-names>E. L.</given-names>
</name>
</person-group> <source>Methods of inhibiting the action of tnf for neurological conditions by administering etanercept intrathecally, 2016</source>. <comment>US Patent RE45,976</comment>.</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toman</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Faden</surname>
<given-names>A. I.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Role of ceramide in neuronal cell death and differentiation</article-title>. <source>J. Neurotrauma</source> <volume>17</volume> (<issue>10</issue>), <fpage>891</fpage>&#x2013;<lpage>898</lpage>. <pub-id pub-id-type="doi">10.1089/neu.2000.17.891</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valente</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Coronges</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lakon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Costenbader</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>How correlated are network centrality measures?</article-title> <source>Connect.</source> <volume>28</volume> (<issue>1</issue>), <fpage>16</fpage>&#x2013;<lpage>26</lpage>. </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Kruining</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>van Echten-Deckert</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mielke</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>159</volume>, <fpage>232</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.04.009</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wajant</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Siegmund</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Tnfr1 and tnfr2 in the control of the life and death balance of macrophages</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>7</volume>, <fpage>91</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2019.00091</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiegmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schwandner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Krut</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>W.-C.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Requirement of fadd for tumor necrosis factor-induced activation of acid sphingomyelinase</article-title>. <source>J. Biol. Chem.</source> <volume>274</volume> (<issue>9</issue>), <fpage>5267</fpage>&#x2013;<lpage>5270</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.9.5267</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wronowska</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Charzy&#x144;ska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niena&#x142;towski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Anna</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Computational modeling of sphingolipid metabolism</article-title>. <source>BMC Syst. Biol.</source> <volume>9</volume> (<issue>1</issue>), <fpage>47</fpage>. <pub-id pub-id-type="doi">10.1186/s12918-015-0176-9</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>C.-K.</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pizzo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Geula</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Apoptotic signals within the basal forebrain cholinergic neurons in alzheimer&#x2019;s disease</article-title>. <source>Exp. Neurol.</source> <volume>195</volume> (<issue>2</issue>), <fpage>484</fpage>&#x2013;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2005.06.020</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Muruato</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lokugamage</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Fontes-Garfias</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A nanoluciferase sars-cov-2 for rapid neutralization testing and screening of anti-infective drugs for Covid-19</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19055-7</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Inflammatory cytokines: Potential biomarkers of immunologic dysfunction in autism spectrum disorders</article-title>. <source>Mediat. Inflamm.</source>, <volume>2015</volume>, <fpage>531518</fpage>. <pub-id pub-id-type="doi">10.1155/2015/531518</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Uncovering the pharmacological mechanism of stemazole in the treatment of neurodegenerative diseases based on a network pharmacology approach</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>2</issue>), <fpage>427</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21020427</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cribbs</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Wasserman</surname>
<given-names>A. J.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>The induction of the tnf<italic>&#x3b1;</italic> death domain signaling pathway in alzheimer&#x2019;s disease brain</article-title>. <source>Neurochem. Res.</source> <volume>28</volume> (<issue>2</issue>), <fpage>307</fpage>&#x2013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1023/a:1022337519035</pub-id> </citation>
</ref>
</ref-list>
<sec id="s12">
<title>Nomenclature</title>
<def-list>
<def-item>
<term id="G1-fphys.2022.872421">
<bold>actAKT</bold>
</term>
<def>
<p>Protein kinase B (activated)</p>
</def>
</def-item>
<def-item>
<term id="G2-fphys.2022.872421">
<bold>actBID</bold>
</term>
<def>
<p>BH3 Interacting-domain Death agonist (activated)</p>
</def>
</def-item>
<def-item>
<term id="G3-fphys.2022.872421">
<bold>actCAPK</bold>
</term>
<def>
<p>Ceramide Activated Protein Kinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G4-fphys.2022.872421">
<bold>actCAPP</bold>
</term>
<def>
<p>Ceramide Activated Protein Phosphatase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G5-fphys.2022.872421">
<bold>actCASP2</bold>
</term>
<def>
<p>Caspase 2 (activated)</p>
</def>
</def-item>
<def-item>
<term id="G6-fphys.2022.872421">
<bold>actCASP3and9</bold>
</term>
<def>
<p>Caspases 3 and 9 (activated)</p>
</def>
</def-item>
<def-item>
<term id="G7-fphys.2022.872421">
<bold>actCASP8</bold>
</term>
<def>
<p>Caspase 8 (activated)</p>
</def>
</def-item>
<def-item>
<term id="G8-fphys.2022.872421">
<bold>actCathepsinD</bold>
</term>
<def>
<p>Cathepsin D (activated)</p>
</def>
</def-item>
<def-item>
<term id="G9-fphys.2022.872421">
<bold>actMEK</bold>
</term>
<def>
<p>Mitogen-activated Protein Kinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G10-fphys.2022.872421">
<bold>actNF<italic>&#x3ba;</italic>B</bold>
</term>
<def>
<p>Nuclear Factor kappa B (activated)</p>
</def>
</def-item>
<def-item>
<term id="G11-fphys.2022.872421">
<bold>actNIK</bold>
</term>
<def>
<p>NF-<italic>&#x3ba;</italic>B-Inducing Kinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G12-fphys.2022.872421">
<bold>actPI3K</bold>
</term>
<def>
<p>phosphoinositide 3-kinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G13-fphys.2022.872421">
<bold>actRAF</bold>
</term>
<def>
<p>Rapidly Accelerated Fibrosarcoma kinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G14-fphys.2022.872421">
<bold>actS1PR</bold>
</term>
<def>
<p>Sphingosine-1-Phosphate Receptor (activated)</p>
</def>
</def-item>
<def-item>
<term id="G15-fphys.2022.872421">
<bold>actSMase</bold>
</term>
<def>
<p>Sphingomyelinase (activated)</p>
</def>
</def-item>
<def-item>
<term id="G16-fphys.2022.872421">
<bold>AD</bold>
</term>
<def>
<p>Alzheimer&#x2019;s Disease</p>
</def>
</def-item>
<def-item>
<term id="G17-fphys.2022.872421">
<bold>AKT</bold>
</term>
<def>
<p>Protein Kinase B</p>
</def>
</def-item>
<def-item>
<term id="G18-fphys.2022.872421">
<bold>ASD</bold>
</term>
<def>
<p>Autism Spectrum Disorder</p>
</def>
</def-item>
<def-item>
<term id="G19-fphys.2022.872421">
<bold>BID</bold>
</term>
<def>
<p>BH3 Interacting-Domain Death Agonist</p>
</def>
</def-item>
<def-item>
<term id="G20-fphys.2022.872421">
<bold>CAPK</bold>
</term>
<def>
<p>Ceramide Activated Protein Kinase</p>
</def>
</def-item>
<def-item>
<term id="G21-fphys.2022.872421">
<bold>CAPP</bold>
</term>
<def>
<p>Ceramide Activated Protein Phosphatase</p>
</def>
</def-item>
<def-item>
<term id="G22-fphys.2022.872421">
<bold>CASP 2</bold>
</term>
<def>
<p>Caspase 2</p>
</def>
</def-item>
<def-item>
<term id="G23-fphys.2022.872421">
<bold>CASP 3 and 9</bold>
</term>
<def>
<p>Caspase 3 and 9</p>
</def>
</def-item>
<def-item>
<term id="G24-fphys.2022.872421">
<bold>CDase</bold>
</term>
<def>
<p>Ceramidase</p>
</def>
</def-item>
<def-item>
<term id="G25-fphys.2022.872421">
<bold>cIAP2</bold>
</term>
<def>
<p>Inhibitor of Apoptosis Protein</p>
</def>
</def-item>
<def-item>
<term id="G26-fphys.2022.872421">
<bold>DD</bold>
</term>
<def>
<p>Death Domain</p>
</def>
</def-item>
<def-item>
<term id="G27-fphys.2022.872421">
<bold>ERK</bold>
</term>
<def>
<p>Extracellular Signal-Regulated Kinase</p>
</def>
</def-item>
<def-item>
<term id="G28-fphys.2022.872421">
<bold>FADD</bold>
</term>
<def>
<p>Fas-Associated Protein with Death Domain</p>
</def>
</def-item>
<def-item>
<term id="G29-fphys.2022.872421">
<bold>FAN</bold>
</term>
<def>
<p>Factor Associated with Neutral Sphingomyelinase Activation</p>
</def>
</def-item>
<def-item>
<term id="G30-fphys.2022.872421">
<bold>GAP</bold>
</term>
<def>
<p>GTPase-Activating Protein</p>
</def>
</def-item>
<def-item>
<term id="G31-fphys.2022.872421">
<bold>GDP</bold>
</term>
<def>
<p>Guanosine Diphosphate</p>
</def>
</def-item>
<def-item>
<term id="G32-fphys.2022.872421">
<bold>GTP</bold>
</term>
<def>
<p>Guanosine Triphosphate</p>
</def>
</def-item>
<def-item>
<term id="G33-fphys.2022.872421">
<bold>Gi</bold>
</term>
<def>
<p>G-protein Alpha Subunit</p>
</def>
</def-item>
<def-item>
<term id="G34-fphys.2022.872421">
<bold>Gi Coupled Receptor</bold>
</term>
<def>
<p>G-protein Coupled Receptor</p>
</def>
</def-item>
<def-item>
<term id="G35-fphys.2022.872421">
<bold>IKK</bold>
</term>
<def>
<p>Inhibitor of Nuclear Factor kappa-B Kinase</p>
</def>
</def-item>
<def-item>
<term id="G36-fphys.2022.872421">
<bold>MEK</bold>
</term>
<def>
<p>Mitogen-activated Protein Kinase</p>
</def>
</def-item>
<def-item>
<term id="G37-fphys.2022.872421">
<bold>MS</bold>
</term>
<def>
<p>Multiple sclerosis</p>
</def>
</def-item>
<def-item>
<term id="G38-fphys.2022.872421">
<bold>NF<italic>&#x3ba;</italic>B</bold>
</term>
<def>
<p>Nuclear Factor Kappa B</p>
</def>
</def-item>
<def-item>
<term id="G39-fphys.2022.872421">
<bold>NIK</bold>
</term>
<def>
<p>NF-<italic>&#x3ba;</italic>B Inducing Kinase</p>
</def>
</def-item>
<def-item>
<term id="G40-fphys.2022.872421">
<bold>PD</bold>
</term>
<def>
<p>Parkinson&#x2019;s Disease</p>
</def>
</def-item>
<def-item>
<term id="G41-fphys.2022.872421">
<bold>PDK1</bold>
</term>
<def>
<p>Phosphoinositide-Dependent Kinase-1</p>
</def>
</def-item>
<def-item>
<term id="G42-fphys.2022.872421">
<bold>PhIKK</bold>
</term>
<def>
<p>Inhibitor of Nuclear Factor Kappa-B Kinase (phosphorylated)</p>
</def>
</def-item>
<def-item>
<term id="G43-fphys.2022.872421">
<bold>PI3K</bold>
</term>
<def>
<p>phosphoinositide 3-kinase</p>
</def>
</def-item>
<def-item>
<term id="G44-fphys.2022.872421">
<bold>PIP2</bold>
</term>
<def>
<p>Phosphatidylinositol 4,5-Bisphosphate</p>
</def>
</def-item>
<def-item>
<term id="G45-fphys.2022.872421">
<bold>PIP3</bold>
</term>
<def>
<p>Phosphatidylinositol (3,4,5)-Trisphosphate</p>
</def>
</def-item>
<def-item>
<term id="G46-fphys.2022.872421">
<bold>PKC</bold>
</term>
<def>
<p>Protein kinase C</p>
</def>
</def-item>
<def-item>
<term id="G47-fphys.2022.872421">
<bold>proCASP 8</bold>
</term>
<def>
<p>Procaspase-8</p>
</def>
</def-item>
<def-item>
<term id="G48-fphys.2022.872421">
<bold>ProtCathepD</bold>
</term>
<def>
<p>Protease Cathepsin D</p>
</def>
</def-item>
<def-item>
<term id="G49-fphys.2022.872421">
<bold>RAF</bold>
</term>
<def>
<p>Rapidly Accelerated Fibrosarcoma</p>
</def>
</def-item>
<def-item>
<term id="G50-fphys.2022.872421">
<bold>RAIDD</bold>
</term>
<def>
<p>RIP-Associated Protein with a Death Domain</p>
</def>
</def-item>
<def-item>
<term id="G51-fphys.2022.872421">
<bold>RasGDP</bold>
</term>
<def>
<p>GDP-bound state of Ras</p>
</def>
</def-item>
<def-item>
<term id="G52-fphys.2022.872421">
<bold>RasGTP</bold>
</term>
<def>
<p>GTP-bound state of Ras</p>
</def>
</def-item>
<def-item>
<term id="G53-fphys.2022.872421">
<bold>recruitRAIDD</bold>
</term>
<def>
<p>recruited RIP-Associated Protein with a Death Domain</p>
</def>
</def-item>
<def-item>
<term id="G54-fphys.2022.872421">
<bold>recruit AKT</bold>
</term>
<def>
<p>recruited Protein Kinase B</p>
</def>
</def-item>
<def-item>
<term id="G55-fphys.2022.872421">
<bold>recruit FADD</bold>
</term>
<def>
<p>recruited Fas-Associated Protein with Death Domain</p>
</def>
</def-item>
<def-item>
<term id="G56-fphys.2022.872421">
<bold>recruit RIP</bold>
</term>
<def>
<p>recruited Receptor-Interacting Protein Kinase</p>
</def>
</def-item>
<def-item>
<term id="G57-fphys.2022.872421">
<bold>RIP</bold>
</term>
<def>
<p>Receptor-Interacting Protein Kinase</p>
</def>
</def-item>
<def-item>
<term id="G58-fphys.2022.872421">
<bold>RIP_RAIDD</bold>
</term>
<def>
<p>RIP RAIDD complex</p>
</def>
</def-item>
<def-item>
<term id="G59-fphys.2022.872421">
<bold>S1P</bold>
</term>
<def>
<p>Sphingosine 1 Phosphate</p>
</def>
</def-item>
<def-item>
<term id="G60-fphys.2022.872421">
<bold>S1PR</bold>
</term>
<def>
<p>Sphingosine-1-Phosphate Receptor</p>
</def>
</def-item>
<def-item>
<term id="G61-fphys.2022.872421">
<bold>SM</bold>
</term>
<def>
<p>Sphingomyelin</p>
</def>
</def-item>
<def-item>
<term id="G62-fphys.2022.872421">
<bold>SMase</bold>
</term>
<def>
<p>Sphingomyelinase</p>
</def>
</def-item>
<def-item>
<term id="G63-fphys.2022.872421">
<bold>SMase(translocated)</bold>
</term>
<def>
<p>Sphingomyelinase (translocated)</p>
</def>
</def-item>
<def-item>
<term id="G64-fphys.2022.872421">
<bold>SMS</bold>
</term>
<def>
<p>Sphingomyelin Synthase</p>
</def>
</def-item>
<def-item>
<term id="G65-fphys.2022.872421">
<bold>SPHK</bold>
</term>
<def>
<p>Sphingosine Kinase</p>
</def>
</def-item>
<def-item>
<term id="G66-fphys.2022.872421">
<bold>TNF-<italic>&#x3b1;</italic>
</bold>
</term>
<def>
<p>Tumor Necrosis Factor-<italic>&#x3b1;</italic>
</p>
</def>
</def-item>
<def-item>
<term id="G67-fphys.2022.872421">
<bold>TNFR</bold>
</term>
<def>
<p>Tumor Necrosis Factor Receptor</p>
</def>
</def-item>
<def-item>
<term id="G68-fphys.2022.872421">
<bold>TNFR_FAN</bold>
</term>
<def>
<p>Complex of TNFR and FAN</p>
</def>
</def-item>
<def-item>
<term id="G69-fphys.2022.872421">
<bold>TNFR_TNF</bold>
</term>
<def>
<p>Complex of TNFR and TNF</p>
</def>
</def-item>
<def-item>
<term id="G70-fphys.2022.872421">
<bold>TNFR_TRADD</bold>
</term>
<def>
<p>Complex of TNFR and TRADD</p>
</def>
</def-item>
<def-item>
<term id="G71-fphys.2022.872421">
<bold>TRADD</bold>
</term>
<def>
<p>Tumor Necrosis Factor Receptor type 1-Associated Death Domain Protein</p>
</def>
</def-item>
<def-item>
<term id="G72-fphys.2022.872421">
<bold>TRADD_TRAF2</bold>
</term>
<def>
<p>Complex of TRADD</p>
</def>
</def-item>
<def-item>
<term id="G73-fphys.2022.872421">
<bold>TRAF2_TRAF2</bold>
</term>
<def>
<p>TNF Receptor-Associated Factor 2</p>
</def>
</def-item>
<def-item>
<term id="G74-fphys.2022.872421">
<bold>RTU</bold>
</term>
<def>
<p>Relative Time Unit</p>
</def>
</def-item>
<def-item>
<term id="G75-fphys.2022.872421">
<bold>RC</bold>
</term>
<def>
<p>Relative Concentration</p>
</def>
</def-item>
</def-list>
</sec>
</back>
</article>